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THE ROLE OF THE MIR-200 FAMILY ON THE TUMOR SUPPRESSOR RASSF2 
AND THE EFFECT ON MAPK PATHWAY ACTIVITY IN COLORECTAL CANCER 
Jane V. Carter 
November 22nd 2016 
 
 This dissertation investigated the role of the miR-200 family in normal colon 
epithelial (CCD 841) and Dukes’ C (HT-29) colorectal cancer (CRC) cell lines. Our aim 
was to characterize expression of the miR-200 family (miR-200a, miR-200b, miR-200c, 
miR-141, and miR-429) in colorectal cell lines, study their effect on the tumor suppressor 
Ras Associated Domain-Containing Protein (RASSF) 2 and on subsequent activity within 
the mitogen-activated protein kinase (MAPK) signaling pathway. We wanted to 
determine whether regulation of miR-200 family members could change cell behavior 
towards more “cancer-like” in a normal colon epithelium (CCD 841) cell line, or less 
“cancer-like” in a  Dukes’ C (HT-29) CRC cell line.  
We found the following: 
1. All miR-200 family members were highly expressed in colorectal cancer cell lines 
compared to a normal colon epithelial cell line. 
 viii 
 
2. RASSF2 mRNA and protein expression was downregulated in all CRC cell lines 
compared to the normal colon epithelial (CCD 841) cell line. 
3. Overexpression of miR-200 family members in a normal colon epithelial (CCD 
841) cell line decreased expression of both RASSF2 mRNA and protein. 
4. Inhibition of miR-200 family members in a Dukes’ C (HT-29) CRC cell line 
increased expression of both RASSF2 mRNA and protein. 
5. Total K-Ras expression and phosphorylation of ERK 1/2 increased following 
overexpression of miR-200 family members in a normal colon epithelial (CCD 
841) cell line, indicating increased activity within the MAPK pathway resulting in 
increased cell proliferation. 
6. MAPK pathway activity decreased, as measured by reduced ERK 1/2 
phosphorylation and reduced cell proliferation in a Dukes’ C (HT-29) CRC cell 
line following inhibition of miR-200 family members.  
These findings demonstrate a novel association of the miR-200 family, the tumor 
suppressor RASSF2, and the MAPK signaling pathway in CRC. In contrast to the 
previous understanding that miR-200 family dysregulation is considered to exhibit tumor 
suppressive behavior by blocking epithelial to mesenchymal transition, we refute this in 
the case of CRC and propose the miR-200 family contribute to CRC tumorigenesis. This 
improved understanding of the miR-200 family may have the potential to be developed as 
a therapeutic intervention in CRC. 
 ix 
 
TABLE OF CONTENTS 
Dedication …………………………………………………………………………... iii 
Acknowledgements………………………………………………………………….. iv 
Abstract……………………………………………………………………………… vii 
List of Tables………………………………………………………………………… xiii 
List of Figures………………………………………………………………………... xiv 
Preface………………………………………………………...................................... xviii 
 
Chapter          Page 
I. INTRODUCTION……………………………………………………………... 1 
 Epidemiology and Risk Factors for the Development of Colorectal  
 Cancer………………………………………………………………………….. 1 
 Diagnosis, Staging and Treatment of Colorectal Cancer………………………. 5 
II. MOLECULAR MECHANISMS OF COLORECTAL CARCINOGENESIS… 13 
 KRAS…………………………………………………………………………... 21 




III. MICRORNAS AND COLORECTAL CANCER……………………………... 25 
 Overview and biogenesis………………………………………………………. 25 
 microRNAs as Biomarkers for Diagnosis of Colorectal Cancer……………… 26 
 miRNAs and Colorectal Cancer Prognosis……………………………………. 31 
 miRNAs and Response to Chemotherapy in Colorectal Cancer………………. 32 
IV. COLORECTAL CANCER CELL LINE SCREENING………………………. 34 
 Ingenuity Pathway Analysis…………………………………………………… 44 
 microRNA-200 Family………………………………………………………… 48 
 RASSF2………………………………………………………………………... 53 
V. HYPOTHESIS, SPECIFIC AIMS, AND EXPERIMENTAL PLAN…………. 55 
 Key Objective………………………………………………………………….. 55 
 Hypothesis……………………………………………………………………... 55 
 Specific Aims…………………………………………………………………... 56 
 Experimental Plan……………………………………………………………… 56 
VI. MATERIALS AND METHODS………………………………………………. 59 
 Cell Lines………………………………………………………………………. 59 
 Maintenance of Cell Lines……………………………………………………... 61 
 Harvesting Cells for RNA……………………………………………………… 69 
 Harvesting Cells for Protein…………………………………………………….70 
 Total RNA Isolation……………………………………………………………. 70  
 microRNA Screening of Cell Lines……………………………………………. 71 
 xi 
 
 microRNA Single Assay Validation…………………………………………… 75 
 messengerRNA (mRNA) Quantification………………………………………. 78 
 microRNA Transfection………………………………………………………...79 
 Protein Quantification………………………………………………………….. 82 
 Western Blot…………………………………………………………………… 83 
 Cell Proliferation……………………………………………………………….. 85 
 Enzyme-Linked Immunosorbent Assay (ELISA)……………………………… 86 
 Statistical Methods and Analytic Techniques…………………………………. 87 
VII. COLORECTAL CANCER CELL LINE EXPRESSION OF RASSF2 MRNA 
AND PROTEIN………………………………………………………………... 90 
 Introduction…………………………………………………………………….. 90 
 Results………………………………………………………………………….. 91 
 Discussion……………………………………………………………………… 96 
VIII. GAIN OF FUNCTION OF MIR-200 FAMILY IN A NORMAL COLON 
EPITHELIAL (CCD 841) CELL LINE………………………………………... 99  
 Introduction…………………………………………………………………….. 99 
 Results………………………………………………………………………….. 100 
 Discussion……………………………………………………………………… 107 
IX. LOSS OF FUNCTION OF MIR-200 FAMILY IN A DUKES’ C (HT-29) 
COLORECTAL CANCER CELL LINE………………………………………. 111 
 Introduction…………………………………………………………………….. 111 
 Results………………………………………………………………………….. 112 
 xii 
 
 Discussion……………………………………………………………………… 117 
X. MAPK PATHWAY ACTIVATION AND CELL PROLIFERATION……….. 122 
 Introduction…………………………………………………………………….. 122 
 Results………………………………………………………………………….. 124 
 Discussion……………………………………………………………………… 135 
XI. CONCLUDING REMARKS AND DIRECTION OF FUTURE STUDIES….. 143 
REFERENCES………………………………………………………………………… 150 
APPENDIX: ABBREVIATIONS……………………………………………………... 172 
OTHER PUBLICATIONS DURING TIME OF PHD STUDIES…………………….. 178 




LIST OF TABLES 
Table 
1 Modified AJCC TNM Staging and Corresponding Dukes’ Classification  .................9 
2  Significantly Dysregulated miRNAs in Colorectal Cancer Cell Lines Compared to a 
Normal Colon Epithelial Cell Line  ...........................................................................37 
3 The Most Significantly Up-regulated and Downregulated miRNAs in Localized 
Colorectal Cancer Cell Lines (Dukes’ A SW1116, and B SW480) Compared to the 
Normal Colon Epithelial Cell Line (CCD 841) and Corresponding Fold Change ....38 
4 The Most Significantly Up-regulated and Downregulated miRNAs in Metastatic 
Colorectal Cancer Cell Lines (Dukes’ C HT-29 and D T84) Compared to the Normal 
Colon Epithelial Cell Line (CCD 841) and Corresponding Fold Change ..................39 
5  miR-200 Family Expression in Colorectal Cancer Cell Line Screening  ...................42 
6  Single Assay miRNA Validation of miR-200 Family in Colorectal Cancer Cell Lines 
Compared to a Normal Colon Epithelial Cell Line (CCD 841) .................................43 
7  Characteristics of Cell Lines  .....................................................................................63 
8  Total RNA Concentration and Purity of Normal Colon Epithelial and Dukes’ 
Colorectal Cancer Cell Lysates used for miRNA Cell Line Screening  ....................72 
9  Total RNA Concentration and Purity following Transfection with miR-200 Family 
Mimics and Antagomirs  ............................................................................................73 
10  Transfection Protocol Procedure Details  ...................................................................81 
11  MAPK Pathway Proteins of Interest with Molecular Weight and Primary and 
Secondary Antibody Dilutions  ..................................................................................84 
12  Average Cycle Threshold and ΔΔCt Values, and Fold Regulation for Expression of 
RASSF2 mRNA in All Colorectal Cell Lines  ...........................................................94
 xiv 
 
LIST OF FIGURES 
Figure 
1 Estimated New Cases of Colorectal Cancer in the United States 2015 ...................... 2 
2  Estimated Colorectal Cancer Deaths in the United States 2015 ................................. 3 
3  Percent of Cases and 5-Year Relative Survival by Stage at Diagnosis for Colorectal 
Cancer .......................................................................................................................... 4 
4  Tumor Node Metastases (TNM) Staging of Colon Cancer ......................................... 8 
5  Dukes’ Classification of Colon Cancer ..................................................................... 10 
6  The Chromosomal Instability Pathway (CIN) in Colon Cancer ............................... 16 
7 The Serrated Polyp Pathway in Colon Cancer .......................................................... 17 
8  Schematic Representation of Several Overlapping Pathways Involved in the 
Development of Colorectal Cancer ........................................................................... 20 
9  Schematic Overview of the ERK MAPK Pathway ................................................... 24 
10  microRNA Biogenesis ............................................................................................... 27 
11  Waterfall Plot of the Significantly Dysregulated miRNAs in Localized Colorectal 
Cancer Cell Lines (Dukes’ A SW1116 and B SW480) as Compared to the Normal 
Colon Epithelial Cell Line (CCD 841) ...................................................................... 40 
12  Waterfall Plot of the Significantly Dysregulated miRNAs in Metastatic Colorectal 
Cancer Cell Lines (Dukes’ C HT-29 and D T84) as Compared to the Normal Colon 
Epithelial Cell Line (CCD 841) ................................................................................. 41
 xv 
 
13  ERK MAPK Signaling and miRNAs Results from Ingenuity Pathway Analysis .... 45 
14  miR-200a Targets Identified by miRTarBase ........................................................... 46 
15  miR-200 Family and its Target RASSF2 as Identified by miRTarBase  .................. 47 
16  Genomic Location of miR-200 Family and Seed Sequence of Functional Groups 1 
and 2. ......................................................................................................................... 49 
17  Epithelial to Mesenchymal Transition ...................................................................... 50 
18  Hypothesis Overview. ............................................................................................... 58 
19  Morphology and Growth of Cell Lines CCD 841 CoN – Normal Colon Epithelium
 .................................................................................................................................. .64 
20  Morphology and Growth of Cell Lines SW1116 – Dukes’ A CRC .......................... 65 
21  Morphology and Growth of Cell Lines SW480 – Dukes’ B CRC ............................ 66 
22  Morphology and Growth of Cell Lines HT-29 – Dukes’ C CRC ............................. 67 
23  Morphology and Growth of Cell Lines T84 – Dukes’ D CRC ................................. 68 
24  RASSF2 mRNA Expression in All Colorectal Cell Lines ........................................ 93 
25  RASSF2 mRNA Expression in Colorectal Cancer Cell Lines Compared to a Normal 
Colon Epithelial (CCD 841) Cell Line. ..................................................................... 95 
26  Western Blot Showing Expression of RASSF2 Protein in Normal Colon Epithelium 
(CCD 841) and Dukes’ Colorectal Cancer Cell Lines .............................................. 97 
27  miR-200 Family Members Amplification Plot Following Transfection ................. 102 
28 miR-200 Family Expression in a Normal Colon Epithelial (CCD 841) Cell Line 
Following Transfection with Individual miR-200 Family Mimics. ........................ 103 
 xvi 
 
29  miR-200 Family Expression in a Normal Colon Epithelium (CCD 841) Cell Line 
Following Transfection with All miR-200 Family Mimics in Combination. ......... 104 
30  RASSF2 mRNA Amplification Plot Following Transfection of Normal Colon 
Epithelial (CCD 841) Cell Line with miR-200b ..................................................... 105 
31  RASSF2 mRNA Expression in a Normal Colon Epithelial (CCD 841) Cell Line 
Following Transfection with miR-200 Family Mimics .......................................... 106 
32  Western Blot of RASSF2 Protein in Normal Colon Epithelial Cell Line when 
Transfected with miR-200 Family Mimics ............................................................. 108 
33  RASSF2 Protein Expression in a Normal Colon Epithelial (CCD 841) Cell Line 
Following Transfection with miR-200 Family Mimics.. ........................................ 109 
34  miR-200 Family Expression in a Dukes’ C (HT-29) Cell Line Following 
Transfection with Individual miR-200 Family Antagomirs .................................... 114 
35  miR-200 Family Expression in a Dukes’ C (HT-29) CRC Cell Line Following 
Transfection with All miR-200 Family Antagomirs in Combination ..................... 115 
36 RASSF2 mRNA Expression in a Dukes’ C (HT-29) CRC Cell Line Following 
Transfection with miR-200 Family Antagomirs ..................................................... 116 
37  Western Blot of RASSF2 Protein in Dukes’ C (HT-29) CRC Cell Line Following 
Transfection with miR-200 Family Antagomirs ..................................................... 118 
38  RASSF2 Protein Expression in a Dukes’ C (HT-29) CRC Cell Line Following 
Transfection with miR-200 Family Antagomirs.. ................................................... 119 
39  Association between RASSF2 and K-Ras in the MAPK Pathway ......................... 123 
40  Western Blots for Total K-Ras Protein Expression in a Normal Colon Epithelial 
(CCD 841) Cell Line ............................................................................................... 126 
41  Total K-Ras Protein Expression in a Normal Colon Epithelial (CCD 841) Cell Line 
Following Transfection with miR-200 Family Mimics .......................................... 127 
 xvii 
 
42 Western Blots for Total K-Ras Protein Expression in a Dukes’ C (HT-29) CRC Cell 
Line .......................................................................................................................... 128 
43  Total K-Ras Protein Expression in a Dukes’ C (HT-29) CRC Cell Line Following 
Transfection with miR-200 Family Antagomirs ..................................................... 129 
44  ELISA Measurement of Total and Phosphorylated ERK 1/2 in a Normal Colon 
Epithelial (CCD 841) Cell Line Following Transfection with miR-200 Family 
Mimics ..................................................................................................................... 131 
45  ERK 1/2 Activation in a Normal Colon Epithelial (CCD 841) Cell Line Following 
Transfection with miR-200 Family Mimics ............................................................ 132 
46  ELISA Measurement of Total and Phosphorylated ERK 1/2 in a Dukes’ C (HT-29) 
CRC Cell Line Following Transfection with miR-200 Family Antagomirs ........... 133 
47  ERK 1/2 Activation in a Dukes’ C (HT-29) CRC Cell Line Following Transfection 
with miR-200 Family Antagomirs .......................................................................... 134 
48  Cell Proliferation in a Normal Colon Epithelial (CCD 841) Cell Line Following 
Transfection with miR-200 Family Mimics ............................................................ 136 
49  Cell proliferation growth curves for each miR-200 family member in a Normal 
Colon Epithelial (CCD 841) Cell Line .................................................................... 137 
50  Cell Proliferation in a Dukes’ C (HT-29) CRC Cell Line Following Transfection 
with miR-200 Family Antagomirs. ......................................................................... 138 
51 Cell proliferation growth curves for each miR-200 family member in a Dukes’ C 







 During my general surgical registrar training in the South West of England I was 
fortunate to have the opportunity to conduct research at the Price Institute of Surgical 
Research under the mentorship of Dr. Susan Galandiuk, Louisville, Kentucky.  
I was introduced to a laboratory working with colorectal cancer cell lines and 
microRNAs as biomarkers for the detection of colorectal cancer. It was here I became 
interested in the differential expression of miRNAs between cancers that were locally 
confined (surgically curable) and those that had begun to metastasize (less likely to be 
cured by surgery). As a way of learning laboratory techniques and cell culture I 
performed miRNA screening studies on four colorectal cancer cell lines, two locally 
confined and two metastatic, and one normal colon epithelium, to determine whether 
there were differences in miRNA expression. This resulted in the observation that the 
miR-200 family members were highly expressed in colorectal cancer. Research into the 
miR-200 family identified an association with the tumor suppressor RASSF2 and after 
confirmatory studies, a hypothesis was generated. 
Based upon the screening results and my thesis committee’s advice, a Dukes’ C 
(HT-29) colorectal cancer cell line and a normal colon epithelial (CCD 841) cell line 
were selected for further study. A commonly dysregulated pathway in colorectal cancer is 
the MAPK signaling pathway. This pathway is a major regulator of cell proliferation.
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For this reason we chose to study the effect of the miR-200 family on both proliferation 
in the Dukes’ C (HT-29) colorectal cancer cell line and the normal colon epithelial (CCD 
841) cell line.  
Another goal was to perform gain and loss of function studies of the miR-200 
family with the idea that colorectal cancer cells would adopt less malignant behavior, 
whereas normal colon epithelial cells would have more malignant behavior. 
I have enjoyed learning and understanding the processes involved in scientific 
research and I have deepened my knowledge on aspects contributing to surgical disease. 
This has set the foundations on which I will take back with me to the United Kingdom to 







a) Epidemiology and Risk Factors for the Development of Colorectal Cancer 
Colorectal cancer (CRC) is common worldwide and associated with significant 
mortality. In the United States alone in 2015, CRC was the third most common cancer in 
men and women with approximately 135,000 new cases diagnosed (Figure 1). It was also 
accountable as the third most leading cause of cancer deaths continuing to make CRC an 
enormous public health burden (Figure 2).(1) Most patients present with late stage 
disease and the 5-year survival for patients with newly diagnosed colon cancer with 
distant metastases is less than 15% (Figure 3).(2) Overall, the current lifetime risk of 
developing CRC is approximately 1 in 21 (4.7%) for men and 1 in 23 (4.4%) for 
women.(2)  
The underlying causes of CRC are complex and heterogeneous. Most sporadic 
CRC develops from precursor polyps, namely advanced adenomas and 
hyperplastic/serrated polyps. Adenocarcinomas form more than 95% of all colorectal 
cancers. Other less common types of tumors to develop in the colon and rectum include 
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Available from: http://seercancergov/statfacts/html/colorecthtml [Accessed 28th September 2016].  
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Both environmental and inherited risk factors have also been identified to 
contribute to the development of CRC. Modifiable environmental factors include a high 
fat/high red meat diet, excess alcohol consumption, obesity, smoking, and lack of 
physical activity. Non-modifiable risk factors such as an older age, a personal history of 
colorectal polyps or inflammatory bowel disease, a family history of colorectal cancer in 
a first-degree relative, or having an inherited syndrome can all contribute to the 
development of CRC.  
b) Diagnosis of Colorectal Cancer 
As stated, the majority of colorectal cancer present at a late stage. This is due, in 
part, to a delay in presentation of symptoms and signs associated with CRC. In addition, 
many of these general symptoms, such as abdominal discomfort, bloating, and irregular 
bowel movements, are often caused by other conditions than cancer. “Red flag” signs 
include rectal bleeding, blood within the stool, unintentional weight loss, fatigue and 
unexplained iron-deficiency anemia.  
Colonoscopy is the current “gold-standard” for screening and diagnosis of 
colorectal neoplasia and has >95% sensitivity and 90% specificity.(3) It allows for 
removal of precancerous polyps, and according to case-control and cohort studies, 
decreases both CRC incidence and CRC related mortality.(4-8) Colonoscopy is; however, 
expensive, invasive, has a risk of complications such as bowel perforation, and has a 
relatively high rate of patient non-compliance. The screening interval of 10 years for 
colonoscopy has a detection rate of early CRC of only 18-35%.(9-12) Despite these 
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shortcomings, the broad use of colonoscopy for the last 3 years in the U.S. has been 
associated with a significant decrease in frequency of CRC.(13)  
Flexible sigmoidoscopy has been shown to decrease both CRC incidence as well 
as the mortality of distal CRC.(14) Other “imaging” tests for cancer screening include 
barium enema and virtual colonoscopy. Disadvantages of such screening include 1) high 
patient non-compliance, 2) the invasive nature of such procedures, 3) the need for 
sedation for colonoscopy, 4) rare patient morbidity such as colon perforation,(15) 5) the 
need for vigorous bowel cleansing, and 6) expense.(16) 
Available less-invasive tests include stool-based assays, such as the guaiac and 
immunochemical fecal occult blood tests (FOBTs) and DNA-based tests.(17) Although 
immunochemical FOBTs are superior to guaiac FOBTs, their ability to detect 
premalignant colorectal adenomas is limited. A recent German prospective screening 
study assessed the two best-performing immunohistochemical FOBTs and determined the 
sensitivity for detection of advanced adenomas of 25% and 27%.(18) Stool-based DNA 
testing identified 54% of patients with adenomas >1 cm in size with 90% specificity.(19) 
Due to the nature of the tested substance, stool-based testing is not popular among 
patients, physicians, or lab personnel. A stool-based bowel-screening program in the 
United Kingdom found that only 50% participated in screening; and of those with an 
abnormal guaiac FOBT, only 83% underwent subsequent colonoscopy.(20) 
The only plasma-based assay that has been regularly available for clinical 
monitoring, and, in some cases, for CRC screening, has been the carcinoembryonic 
antigen (CEA) assay, which is also used for post-operative surveillance and for 
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monitoring response to therapy. CEA lacks sufficient sensitivity and specificity (36-74% 
and 87% respectively) for use as a population screening tool or for detecting CRC 
recurrence.(21, 22) Carbohydrate antigen 19-9 (CA 19-9) has also been used as a 
prognostic tumor marker, but it is even less sensitive than CEA for CRC.(23) Recently, 
CA11-19, has been identified as a promising serologic tumor marker which has been 
reported to detect early CRC with a sensitivity of 98% and specificity of 84%.(24) 
c) Colorectal Cancer Staging 
 Cancer staging is performed for diagnostic purposes and to also determine the 
best treatment for patients. Staging in CRC refers to the extent of local invasion, the 
degree of lymph node involvement, and whether there is distant metastasis. The most 
common and accepted staging system from the American Join Committee on Cancer 
(AJCC) is called the Tumor Node Metastases (TNM) system. This system is comprised 
of three categories, where by “T” represents the degree of invasion of cancer into the 
bowel wall, “N” the amount of lymph node involvement, and “M” to the presence of 
metastasis (Figure 4) (Table 1). The older Dukes’ staging of colorectal cancer, described 
by a British pathologist in the 1930’s and more commonly used within Europe, has 
largely been replaced by the TNM staging system to ensure a standardized practice of 
reporting. The initial Dukes’ classification was divided into three categories, Dukes’ A, 
B, and C with each stage representing more advanced disease (Figure 5). Modifications 
to the Dukes’ classification have been developed, such as the Astler-Coller classification, 
which subdivided Dukes’ B and C stages, and added a D stage for metastatic disease, to 
allow for more detailed information for the prognosis and management of the cancer.
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Figure 4. Tumor Node Metastases (TNM) Staging of Colon Cancer 
T represents how far the primary tumor has grown into the intestinal wall and 
whether it has invaded nearby surrounding tissues 
N denotes the number of regional lymph nodes infiltrated by disease 
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Figure 5. Dukes’ Classification of Colon Cancer  
 
Dukes’ Stages of Bowel Cancer. Available from: http://www.cancerresearchuk.org/about-cancer/type/bowel-cancer/treatment/dukes-
stages-of-bowel-cancer [Accessed 28th September 2016].
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d) Treatment for Colorectal Cancer 
 For the majority of cases, the mainstay of treatment for colorectal cancer is 
excision of the tumor either surgically or endoscopically. Other adjunct agents include 
chemotherapy, radiation therapy, or targeted therapy. Typically precursor colorectal 
adenomas can be removed via colonoscopy and very early stage cancers can be removed 
by local excision. Early stage disease is best treated surgically with resection of the tumor 
and surrounding tissue to ensure adequate removal of the cancer as demonstrated by the 
absence of tumor cells at the resected surgical margin. Chemotherapy, either adjuvant or 
neoadjuvant, may be indicated in patients presenting with more advanced disease defined 
in the case of colon cancer by lymph node metastasis. Chemotherapy can be administered 
systemically, regionally, or by hepatic artery infusion in cases where the cancer has 
metastasized to the liver. Commonly used chemotherapeutic agents include 5-flurouracil, 
leucovorin, capecitabine, oxaliplatin and irinotecan. Often, two or more of these drugs are 
given in combination to increase their efficacy.  
 Not all CRCs respond to traditional chemotherapy. As research has advanced to 
understand the genetic and protein changes involved in the development of CRC, newer 
drugs have been developed to target these changes. Classes of targeted drugs include 
those that 1) act to stop blood vessel formation by targeting vascular endothelial growth 
factor, a protein involved in angiogenesis, 2) drugs that target epidermal growth factor 
receptor, a protein present on the cell surface that is involved in the growth of cancer 
cells, and 3) drugs that inhibit kinase activity, proteins on or near the surface of cells that 
transmit signals to the control center of cells. 
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 In patients with isolated or few metastases to the liver or lung, it is possible to 
surgically remove these with the primary tumor. For other forms of advanced disease, 
newer techniques such as ablation and embolization therapy can be used to destroy the 
tumor. These methods of treatment are often reserved for patients who are unable to have 
surgery for other reasons, or whose disease burden is so great it cannot be removed 
surgically. Palliative care is a form of medical care used for symptom control in advanced 
and end stage disease in patients. Palliative care can be operative or non-operative 





MOLECULAR MECHANISMS OF COLORECTAL CARCINOGENESIS 
 
Colorectal cancer presents in one of three major forms: inherited, sporadic, and 
familial. Inherited and familial forms of CRC are from germline mutations, with inherited 
CRC accounting for <10% and familial accounting for approximately 25% of all CRC 
cases. Common inherited conditions leading to the development of CRC include Familial 
adenomatous polyposis (FAP), its variant Gardner syndrome, Lynch syndrome 
(hereditary non-polyposis colon cancer), and Peutz-Jeghers syndrome. Each of these 
syndromes are caused by inherited mutations in genes associated with cell growth or 
DNA repair. Sporadic CRC, derived from somatic or acquired gene mutations, is by far 
the most common presentation of CRC, accounting for up to 70% of all cases. It is not 
associated with family history.  
In CRC, three distinct pathways of genomic instability underlie the development 
of sporadic and inherited colorectal carcinogenesis: chromosomal instability (CIN), 
microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP) 
pathway. This thesis will focus only on sporadic CRC and the CIN pathway. 
The CIN pathway, also known as the adenoma-carcinoma sequence, follows a 
predictable progression of genetic mutations and corresponding histologic 
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changes. It is well recognized that the majority of sporadic CRC’s develop from 
adenomas or polyps. Genetic changes drive normal colonic epithelium to invasive cancer 
through a four-step progression: firstly, transformation of normal epithelium to an 
adenoma or polyp, proceeding to an in-situ carcinoma, and ultimately to an invasive and 
metastatic adenocarcinoma. The adenoma-carcinoma sequence is the most common 
colorectal polyp pathway accounting for around 80% of cases, the other 20% being via 
the serrated polyp pathway.  
In this adenoma-carcinoma sequence, normal mechanisms regulating epithelial 
renewal are disrupted. Under normal conditions, surface cells are lost due to apoptosis, 
cell proliferation occurs at the crypt base, and at the luminal surface cells cease 
proliferation and terminally differentiate. As adenoma size increases, this normally 
ordered process in increasingly disrupted, the cells become dysplastic and develop 
invasive potential. Since the 1970’s indirect evidence such as pathologic, epidemiologic 
and observational data has supported this sequence of events. Firstly, residual benign 
adenomatous tissues have been found in resected carcinoma specimens. Secondly, 
malignant foci have been observed in advanced adenomas. Thirdly, longitudinal studies 
have shown that benign polyps develop into invasive CRC over time. Stryker et al. 
observed 226 patients with colonic polyps >1cm in diameter who declined surgical or 
endoscopic resection. At 20-year follow-up, patients had a 24% risk of developing 
invasive adenocarcinoma at the site of the index polyp, and a 35% risk of carcinoma at 
any colonic site. (25) The National Polyp Study also confirmed the hypothesis that CRC 
arises from adenomas by showing that endoscopic polypectomy reduced the risk of 
developing a subsequent CRC. (5)  
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There are well-defined molecular genetic steps within the CIN pathway that 
contribute to the development of invasive carcinoma whereby mutational activation of 
oncogenes and inactivation of tumor suppressor genes occur. (26) The initial step in the 
CIN pathway is identification of a dysplastic aberrant crypt focus, a microscopic mucosal 
lesion that precedes the development of a polyp. (27, 28) At this stage, mutations in the 
adenomatous polyposis coli (APC) gene cause activation of the Wnt signaling pathway. 
Progression to late adenoma and early stage carcinoma requires the activation of the 
KRAS proto-oncogene. Additional malignant transformation is caused by mutations in 
TP53, PIK3CA, and TGF-β pathway genes (Figure 6). (29-31) Key principles defining 
the CIN pathway include multiple genetic mutations, the step-wise progression from 
normal mucosa to invasive carcinoma, and aberrant crypt foci of the colon as the 
precursor to adenoma formation. (28, 32) 
Recent evidence within the last 15 years defines an alternative route to the 
development of CRC. The serrated polyp pathway is responsible for ~20% of all sporadic 
colorectal cancers. Hyperplastic polyps were previously regarded as benign lesions with 
little or no malignant potential. It is now recognized that these polyps form part of a 
heterogeneous group, termed serrated polyps, which are characterized by their saw-
toothed appearance. This group contains three premalignant lesions: the hyperplastic 
polyp, the traditional serrated adenoma, and the sessile serrated adenoma. It is believed 
that the sessile serrated adenoma is the main precursor lesion within this pathway leading 
to the development of CRC (Figure 7). Similar to the CIN pathway, a series of molecular 
















Multistep genetic model of colorectal carcinogenesis. The initial step is formation of aberrant crypt foci following mutations in the 
APC gene. Progression to larger adenomas and early carcinoma require activating mutations in KRAS oncogene TP52 and loss of 
heterozygosity at chromosome 18q Chromosomal instability increases with tumor progression. 













Proposed serrated polyp pathway to MSI colorectal cancer. Characteristic crypt alterations, and epigenetic and genetic alterations 
 
Crockett SD, Snover DC, Ahnen DJ, Baron JA. Sessile serrated adenomas: an evidence-based guide to management. Clin 
Gastroenterol Hepatol. 2015;13(1):11-26 e1.  
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mutation and CpG island methylation which causes inactivation of the MLH1 mismatch 
repair gene resulting in microsatellite instability (MSI). Sessile serrated adenomas are 
also believed to be a significant contributor to development of CIMP and microsatellite 
stable (MSS) carcinomas.(33, 34) 
Defects in mismatch repair genes (MMR) lead to MSI carcinomas. MSI colorectal 
carcinomas account for ~15% of all CRC tumors. The term microsatellite refers to 
repeated short sequences of DNA. In normal conditions within cells MMR enzymes 
correct spontaneous errors within these regions during DNA replication. Defects in MMR 
genes result in a reduced capacity of these cells to repair specific types of DNA damage. 
The majority of MMR defects in sporadic CRC are due to epigenetic silencing of Mut L 
homologue 1 (MLH1) gene expression by promoter hypermethylation.(35) Two 
phenotypes of MSI exist. The first is MSI-High, defined as the presence of instability in 
greater than 30% of markers and characteristically cause silencing of MLH1. Patients 
with MSI-High colorectal cancer tend to be younger, and despite the histological features 
of poor differentiation, patients tend to have a better long-term prognosis than those with 
MSS cancers. MSI-low cancers, defined as the presence of instability in 10-29% of 
markers, do not differ from microsatellite stable tumors and typically arise from the CIN 
pathway.(26) Hereditary Non-Polyposis Colorectal Cancer (HNPCC), as part of Lynch 
Syndrome, is an autosomal dominant disease caused by germline mutations in MMR 
genes. MSI resulting from this genetic defect is seen in more than 95% of all patients 
with HNPCC. HNPCC accounts for up to 5% of all CRC cases.  
CpG island methylated phenotype (CIMP) pathway is the third, and most recently 
described, major molecular pathway involved in colorectal carcinogenesis. A CpG site is 
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a region of DNA where cytosine occurs next to guanine. DNA methylation occurs at 
these sites and 80-90% of all CpG are methylated. The remaining 10% form cluster 
“islands” in the promoter region and are unmethylated in the germ line. When vast 
hypermethylation of the promoter CpG island sites occur, tumor suppressor genes are 
silenced and cancer develops. The precursor lesion is considered to be a sessile serrated 
adenoma.(36) 
Understanding the molecular and genetic differences involved in each pathway in 
colorectal tumorigenesis, as described above, can be difficult. Figure 8 shows a schematic 
representation of several of the overlapping pathways involved in the development of 
colorectal carcinoma.(37) In conclusion sporadic CRC develops via a multistep process 
of specific genetic changes driving tumorigenesis. Single, specific germline mutations 
underlie inherited syndromes, whereas sporadic CRC results from accumulation of 
somatic mutations. The three major molecular carcinogenic pathways are the 
chromosomal instability, microsatellite instability, and CpG Island methylated phenotype 





Figure 8. Schematic representation of several overlapping pathways involved in the 
development of colorectal cancer 
 
Red circles represent mechanisms based on tumor suppressor and mutator pathways.  
Blue circles represent mechanisms based on the precursor lesion (CIN and Serrated 
polyp pathways). 








Kirsten rat sarcoma viral oncogene homolog (KRAS) in Colorectal Cancer 
 1) History 
Ras is a family of small guanosine-nucleotide-binding proteins (G-proteins) 
involved in transmitting signals within cells. In humans, the three most clinically notable 
members of the Ras family of genes are HRAS, KRAS and NRAS. KRAS and HRAS, 
the first of the two Ras genes were identified from studies of cancer-causing viruses, 
namely Kirsten and Harvey sarcoma virus, respectively. (38) These viruses were 
originally discovered in rats by Jennifer Harvey and Werner Kirsten in the 1960’s, 
coining the name Rat sarcoma. (39, 40) Discovery was made in 1982 that a single 
nucleotide substitution within KRAS gene was responsible for activating mutation in 
human cells and transformation of the subsequent protein resulted in various 
malignancies. (41-44)  
2) Function 
The protein product of the normal KRAS gene performs an essential function in 
normal tissue signaling. Mutation within the gene is implicated in the development of 
many cancers, in particular, colorectal cancer. KRAS mutations have been observed in 
some 10% of colorectal adenomas, up to 50% of colorectal adenomas displaying severe 
dysplasia, and 35-45% of colorectal carcinomas.(45-47) Located on human chromosome 
12, KRAS is a membrane-bound guanosine triphosphate/guanosine diphosphate 
(GTP/GDP)-binding protein. It contains four coding exons and one 5” non-coding exon. 
Single nucleotide point mutations in KRAS occur in codons 12 and 13 of exon 2, in 
codon 146 in exon 4, and rarely in codon 61 of exon 3. (48, 49) 
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KRAS acts as a molecular on/off switch downstream of growth factor receptors 
such as the epidermal growth factor receptor (EGFR). Under normal physiologic 
conditions, activation of KRAS occurs from upstream signaling by the exchange of 
bound GDP for GTP. KRAS is a membrane-bound GTPase that cycles between the active 
GTP-bound form and the inactive GDP-bound form. This process is transient due to 
GTPase-activating protein (GAP) mediated GTP hydrolysis. Upon conversion of GTP to 
GDP, KRAS is turned off. When mutations occur, the intrinsic activity of KRAS GTPase 
is impaired which prevent GAPs from GTP hydrolysis, locking the KRAS protein in its 
active GTP-bound form. This results in over activation of downstream proliferative 
signaling pathways. (50) The consequence of this includes increased cell proliferation, 
reduced apoptosis, altered cell metabolism and changes in the tumor microenvironment. 
Mitogen-Activated Protein Kinase (MAPK) Pathway 
 The Mitogen-activated protein kinase (MAPK) pathway is a chain of proteins 
within a cell that communicates signals from cell surface membrane receptors to the 
DNA in the nucleus of a cell. The communication from the cell surface to the nucleus 
occurs through the addition of phosphate groups to neighboring proteins. These steps act 
as “on” or “off” switches, however; when a protein within the pathway is mutated, it can 
cause the pathway to become stuck in either the “on” or “off” position. This is typically a 
necessary step in the development of cancer and is frequently dysregulated in 
approximately one-third of all cancers. 
There are three major subfamilies, namely the extracellular-signal-regulated 
kinases (ERK MAPK, Ras/Raf1/MEK/ERK), the c-jun N-terminal kinase or stress-
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activated protein kinases (JNK or SAPK), and MAPK14. They are located downstream of 
growth-factor receptors, including epidermal growth factor receptors. Overexpression and 
activation of this receptor is commonly observed in CRC. Of these sub families, the ERK 
MAPK pathway is one of the most important for cell proliferation. Several proto-
oncogenes transduce the signals that promote cell growth and differentiation within this 
cascade. (51) It is for these reasons that the ERK MAPK pathway is believed to be 
implicated in the pathogenesis, progression, and oncogenic behavior of CRC. (52) For 
this reason, kinases within the ERK MAPK pathway have the potential to be used as 
targets for the treatment of CRC. 
The MAPK pathway comprises of three-tiers of protein kinases, MAPK1 - 3, in 
which the top tier activates the subsequent level, which in turn activates the next level. In 
order for activation of the downstream MAPK within the pathway, it is phosphorylated 
by mitogen-activated protein kinase kinase (MAP2K), which in turn has been activated 
by mitogen-activate protein kinase kinase kinase (MAP3K).  
The initial step to activate the ERK MAPK pathway is through extracellular 
signals transmitted via protein kinase C (PKC) or Ras. PKC activity promotes binding of 
GTP to members of the Ras family, leading to activation of Raf. Raf (MAP3K) 
phosphorylates MEK1 and MEK2 (MAP2K), which in turn phosphorylates ERK 1/2 
(MAP1K). MEK1 and MEK2, also known as ERK kinases, are dual-specificity protein 
kinases that function to control cell growth and differentiation within the MAPK cascade. 
Activation of ERK results in migration of enzymes to the nucleus of the cell, where 
phosphorylation of transcription factors regulate genes that increase cell proliferation and 
reduce apoptosis (Figure 9).(53)  
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Figure 9. Schematic Overview of the ERK MAPK Pathway 
 
 
Extracellular signal proteins bind to receptor tyrosine kinases. K-Ras is activated by 
binding to GTP. Active K-Ras binds to Raf1 and initiates a phosphorylation cascade. 
Downstream transcription factors are affected leading to altered gene expression. 
 




MICRORNAs AND COLORECTAL CANCER 
 
a) Overview and Biogenesis 
microRNAs (miRNAs) are recognized to play a crucial role in the regulation of 
cell function through specific interactions with their messenger RNA (mRNA) 
counterparts. They are small, naturally occurring, non-protein coding RNA molecules 
that downregulate gene expression and affect subsequent protein expression. A single 
miRNA can bind to and regulate many different mRNA targets and, conversely, several 
different miRNAs can bind to and jointly control a single mRNA. 
miRNAs are transcribed in the nucleus as large RNA precursors called primary-
miRNAs (pri-miRNAs) (54). These pri-miRNAs are enzymatically cleaved in the nucleus 
by the enzyme Drosha into precursor miRNA (pre-miRNA). (55) The resulting 
approximately 70-nucleotide pre-miRNA are folded into stem-loop structures. These pre-
miRNAs are then exported into the cytoplasm by the GTP-dependent transport protein 
exportin 5. (56) Once in the cytoplasm, they undergo additional processing by the 
enzyme Dicer to generate the mature double-stranded miRNA approximately 22 
nucleotides in length. Dicer also initiates the formation of the RNA-induced silencing 
complex (RISC). (57) It is in this final part of miRNA biogenesis that the leading miRNA 
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strand is incorporated into the RISC complex, which is then guided into the 
complementary 3’ or 5’ untranslated region of the target mRNA. The RISC is responsible 
for the gene silencing observed due to miRNA expression and RNA interference (Figure 
10). (58) miRNAs cause translational repression, target degradation or gene silencing and 
therefore affect subsequent protein expression. 
miRNAs exhibit a variety of crucial regulatory functions related to cell growth, 
development, and differentiation. (59, 60) miRNAs can function as either tumor 
suppressor genes or oncogenes. Overexpression of miRNAs in cancer may function as 
oncogenes and promote oncogenesis by down-regulating tumor suppressors or other 
genes involved in cell differentiation. In contrast, miRNAs in cancer may function as 
tumor suppressors by inhibiting oncogenesis via down-regulation of proteins with 
oncogenic qualities. (61, 62) Studying the specific function of miRNAs in human 
carcinogenesis will help to identify new targets for cancer research, diagnosis and 
treatment. 
b) microRNAs as Biomarkers for Diagnosis of Colorectal Cancer 
Biological markers or biomarkers are defined as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes or pharmacological responses to a therapeutic intervention”. (63) 
Biomarkers, such as blood, urine and cerebrospinal fluid, can be used for screening, 
diagnosis, and predicting prognosis in human diseases. (64) Plasma and serum are 




Figure 10. microRNA Biogenesis 
MicroRNAs are transcribed from DNA into pri-microRNA and are then processed by 
Drosha into the pre-microRNA. The pre-microRNA is transported into the cytoplasm by 
Exportin-5 and processed by Dicer and integrated into the RNA-induced silencing 
complex (RISC). The complementarity of the microRNA-seed sequence determines the 
effect on the target mRNA: a 100% match results in the degradation of the mRNA 
whereas an 80% match inhibits protein production. Drosha and Dicer are RNA-
processing enzyme located in the nucleus or cytoplasm, respectively. miRNAs circulate in 
various secreted extracellular vesicles, such as microvesicles, apoptotic bodies and 
exosomes, or bound to proteins.  
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composition to plasma except for lacking clotting factors. Both plasma and serum contain 
hormones, glucose, electrolytes, antibodies, antigens and nutrients making them ideal 
media in diagnostic testing. (65) The most commonly used blood-based CRC biomarker, 
carcinoembryonic antigen (CEA), which is used for post-operative surveillance and for 
monitoring response to therapy, lacks sensitivity and specificity for screening or for the 
detection of recurrent CRC (see also pg. 6-7). (21) 
Significant advances have occurred in the field of tumor-associated miRNAs 
since their first discovery in plasma as the number of studies investigating their 
expression has markedly increased in recent years. (66, 67) Although colonoscopy 
remains the gold standard screening test for the diagnosis of CRC, the evaluation of 
miRNA within plasma and/or serum of circulating blood has provided a new area for 
biomarker research. (4, 6, 7, 68) 
miRNAs are stable in extracellular fluid since they are protected from RNases by 
virtue of being bound to argonaute proteins. (69) Discovery of dysregulated miRNA 
expression has been identified in colorectal, esophageal, lung, liver, pancreatic, bladder, 
ovarian, and gastric cancers.(70, 71) miRNAs have been identified in numerous body 
fluids, such as plasma, saliva, feces, and urine. (67, 72) These factors suggest that 
miRNAs can be used as biomarkers for cancer and other disease states. (73) 
The miR-17-92 cluster, also known as oncomiR-1 was the first miRNA 
“oncogene” to be described. (74) Six miRNAs form this miR-17-92 cluster: miR-17, 
miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1 and are known to be 
dysregulated in many cancers. (75) miR-17-92 is overexpressed in both tissue and serum 
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of CRC patients. (76, 77)  In a recent systematic review, 5 of the 6 members of this 
cluster, with the exception of miR-19b-1, were significantly upregulated in the serum or 
plasma of CRC patients as compared to controls in 8 studies. (77-84) The most predictive 
miRNA was miR-92a with area under the curve (AUC) values ranging from 0.786 to 
0.890, 65.5 to 89% sensitivity and 70 to 82.5% specificity. The remaining member of the 
cluster, miR-19b-1, was also significantly upregulated in CRC patients when combined 
as a 2 miRNA panel together with miR-19a, with an AUC of 0.82, 78.57% sensitivity and 
77.36% specificity. (85) These data support the oncogenic role of the miR-17-92 cluster 
in CRC. 
miR-21 has been identified in multiple studies to be upregulated in CRC patients 
as compared to healthy controls. Kanaan et al. identified miR-21 as a biomarker for CRC. 
(72) Validated CRC tissue miRNAs were evaluated in a plasma test set consisting of 30 
CRC patients and 30 healthy controls. The most dysregulated tissue miRNAs were then 
validated in different cohort of 20 CRC patients with 20 age- and race-matched subjects 
without CRC. In the plasma test group, miR-21 differentiated CRC patients from controls 
with an AUC 0.910 and a 90% specificity and sensitivity. (72) Following this, 6 groups 
reproduced similar results with AUC’s ranging from 0.647 – 0.927, 65 – 87.5% 
sensitivity and 74.4 – 93.2% specificity. Although these data were promising, 
dysregulation of miR-21 has been described in many other cancers. (86-93) There is 
therefore need for a plasma miRNA profile specific for CRC. 
miR-29a is another miRNA that has been reported to be upregulated in CRC 
patients in 3 studies. (78, 80, 94) miR-29a is part of the miR-29 family (miR-29a, miR-
29b, miR-29c). Interestingly, another member of the miR-29 family, miR-29b, was 
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observed to be downregulated in CRC compared to control subjects in 2 studies. (95, 96) 
Members of the miR-29 family exhibit differential regulation, implying that their 
functional relevance may not be identical. (97) miR-29b has been shown to function as a 
tumor suppressor in various cancers and diseases (98), while miR-29a has been shown to 
act as a tumor suppressor in lung cancer (99), but as an oncogene in CRC, ovarian and 
breast cancer. (100, 101) 
In order to reduce CRC associated mortality, the ideal biomarker would be able to 
identify individuals with both early stage CRC and its precursor lesion, the colorectal 
advanced adenoma (CAA), from healthy control subjects. CAA are defined as adenomas 
with a villous component, those with high grade dysplasia, or size greater than 0.75cm 
size in diameter. (102) In the studies included in the same recent review, 7 studies 
evaluated miRNAs found to be significantly dysregulated in CRC patients, and in 420 
patients with CAA. Five of these 7 studies reported miRNA panels significantly 
upregulated in CAA as compared to healthy controls. (78, 81, 82, 103, 104) One study 
also identified a panel of 5 miRNAs that distinguished between CRC and CAA with an 
AUC of 0.856. (103) The remaining 2 studies found no significant differences in miRNA 
profile between CAA and healthy controls. (85, 105)  
Identification of numerous miRNAs associated with colorectal carcinogenesis 
demonstrates that miRNAs can distinguish patients with CRC from healthy controls with 
high sensitivity and specificity comparable to that of other common, currently used 
invasive screening methods for CRC.  
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However, no single miRNA has yet been identified as an ideal biomarker for the 
diagnosis of CRC. With deaths from colorectal cancer amongst the leading cause of 
cancer deaths worldwide, there is an emphasis to increase screening, and therefore 
identify early, less invasive stage disease, and to improve survival. For this purpose, 
miRNAs have the potential in the future to be used as a relatively non-invasive, in-
expensive, blood-based marker for the detection of CRC. 
c) miRNAs and Colorectal Cancer Prognosis 
Currently, clinicopathologic tumor staging based on the tumor–node–metastasis 
(TNM) system is the basic prognostic marker for CRC clinical outcomes. The TNM 
system describes the degree to which the tumor has invaded the bowel wall and spread to 
the regional lymph nodes as well as metastasized to distant organs. Although the TNM 
staging system is the mainstay of assessing prognosis, this classification has weaknesses. 
Inadequate examination of lymph nodes may lead to under staging of the tumor and 
subsequent inadequate treatment.(106) Additionally, histologically identical CRC 
patients may have different genetic and epigenetic backgrounds that lead to distinct 
disease progression and clinical outcomes. Unfortunately, no prognostic marker is 
currently available for identifying the patients who would benefit from more-aggressive 
treatments. Recent epigenetic studies have suggested that miRNAs may help to better 
categorize CRC subtypes and predict outcomes. 
miR-21 is one of the most studied and most promising prognostic miRNAs in 
CRC. Increased levels of miR-21 have been correlated with CRC cell proliferation, 
invasion, lymph node metastases, and advanced clinical stage.(107-111)  
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Members of the miR-29 family exhibit differential regulation, implying that their 
functional relevance may not be identical. miR-29a has been identified to be significantly 
elevated in patients with liver metastases in multiple studies,(78, 112, 113) however; in 
other studies, upregulation of miR-29a was associated with a better 12 month 
survival.(114, 115) In addition, elevated levels of another member of the miR-29 family, 
miR-29b, was associated with higher 5-year disease free and overall survival.(116)  
Other miRNAs suggestive of poor prognosis include miR-34b/c, miR-155 and 
miR-130b. Increased expression of each of these miRNAs in CRC tissue is associated 
with poor prognosis and more advanced stage tumors.(117-119) Downregulation of miR-
139-3p in CRC tissue samples was associated with poor survival, especially in those 
patients with early stage (TNM I and II) CRC. (120) 
In order to develop these miRNAs as prognostic markers in CRC, further studies 
validating these miRNAs are required. It is also important to understand the underlying 
mechanisms of each prognostic biomarker, and its respective molecular function, both in 
order to support their clinical use and provide therapeutic targets. 
d) miRNAs and Response to Chemotherapy in Colorectal Cancer 
 Primary treatment of stage I to III CRC’s is surgical resection of the primary 
tumor together with the regional lymph nodes. In patients with high risk stage II and 
stage III disease, adjuvant chemotherapy should be considered. A common chemotherapy 
agent used to treat CRC is 5-fluorouracil (5-FU) a pyrimidine analog. 5-FU metabolism is 
complex, requiring multiple enzymes, including thymidylate synthase (TS). TS catalyzes 
the conversion of deoxyuridine monophosphate (dUMP) to thymidine monophosphate 
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(dTMP), which is one of the three nucleotides that forms thymine (121). Thymine is a 
nucleic acid that is necessary for DNA replication. 5-FU acts to irreversibly inhibit TS, 
essentially starving rapidly dividing cells by halting DNA production.  
 In addition to the potential use of miRNAs as biomarkers for detection and for 
prognosis in CRC patients, several studies have identified miRNAs to predict the 
sensitivity of CRC to chemotherapy. The key to successful treatment is predicting 
response to chemotherapy. It has been suggested that 5-FU could alter miRNA 
expression in colon cancer cells after exposure and treatment thereby affecting the 
mechanisms involved in 5-FU metabolism. (122)    
 A recent review by Hollis et al. identified ten miRNAs to be associated with 
chemosensitivity. Of these, upregulation of miR-21, miR-153, miR-19a, miR-106a, miR-
130b, and miR-484 was associated with increased resistance to 5-FU and other common 
chemotherapy agents. Resistance to chemotherapy was also observed when the following 




COLORECTAL CANCER CELL LINE SCREENING 
 
a) Introduction 
 Cell lines are a common experimental model used to study biological mechanisms 
involved in various diseases. In-vitro cell line studies allow for the investigation of 
signaling pathways, functional processes, identification of molecular markers of disease, 
and testing of cancer therapeutics. As previously described, cancer occurs when a somatic 
cell undergoes a mutation disrupting normal cell cycling resulting in uncontrolled 
proliferation. Immortalized cell lines are a population of cells that can be grown for 
prolonged periods due to similar mutations that enable cells to continually proliferate. It 
is for this reason that cell lines provide an almost unlimited supply of cells with similar 
genotypes and phenotypes for study. The main advantage of this is consistency, 
reproducibility, and the associated relative low-cost. However; questions often arise over 
to what extent the cells actually resemble their tissue of origin after years in culture. The 
most common way to generate an immortalized cell line is by isolating cells from a 
naturally occurring cancer. Whilst cell lines generated in this fashion are known to have 
originated from a specific tissue type, the cells have undergone significant mutation 
allowing for indefinite proliferation. However; for these reasons, caution must be applied 
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when interpreting results as the biology of the cell can be altered. 
 By utilizing well established immortalized CRC cell lines, we are able to 
manipulate cancer pathology in order to gain a better understanding of cancer biology. 
We have chosen to characterize the differential expression of miRNAs in CRC as 
compared to a normal colon epithelial cell line in order to identify potential therapeutic 
targets for intervention. 
b) miRNA Screening of Colorectal Cancer Cell Lines 
 Five immortalized colorectal cell lines, four sporadic colorectal cancer cell lines, 
representing each stage of the Modified Dukes’ classification, and one normal colon 
epithelial cell line used for comparison were studied. Our aim was to characterize the 
differential expression of miRNAs in CRC cell lines as compared to the normal colon 
epithelial cell line in order to identify potential therapeutic targets for intervention (see 
pg. 59 for methods).  
 Comparison of miRNA expression between combined localized stage cancer 
(Dukes’ A and B) and normal colon epithelium, and metastatic stage cancer (Dukes’ C 
and D) and normal colon epithelium was performed (n=4). In order to achieve adequate 
power and group size of four, each sporadic colorectal cancer cell line, SW1116, SW480, 
HT-29 and T84 (Dukes’ A – D, respectively), was screened twice for miRNA expression 
and CCD841, normal colon epithelium, was screened four times.  
 We identified 190 miRNA to be significantly dysregulated, of which 36 were up-
regulated and 154 were downregulated in localized stage CRC (Dukes’ A and B) 
compared to normal colon epithelium. Similarly, 231 miRNAs were significantly 
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dysregulated in metastatic stage CRC (Dukes’ C and D) compared to normal colon 
epithelium, 39 up- and 192 and downregulated, respectively (Table 2). Fold change was 
calculated to assess the magnitude of change between the two groups compared. In 
addition to the p-value, a change was deemed significant when the fold change was > 2-
fold up or down. The twenty most significantly up-regulated and downregulated miRNA 
for each comparison (localized vs. normal and metastatic vs. normal) with their 
corresponding fold change are shown in tables 3 & 4.  Representative waterfall plots are 
shown in figures 11 & 12.   
 Of interest, five of the top eight most significantly up-regulated miRNAs in 
localized stage CRC compared to normal colon epithelium were miR-200a, miR-429, 
miR-141, miR-200b, and miR-200c. Similarly, in metastatic stage CRC compared to 
normal colon epithelium, five of the top six most significantly up-regulated miRNAs 
were these same five miRNAs (Table 5). 
 Single assay miRNA expression was performed in each of the cell lines to 
confirm our findings from screening. Here, miRNA expression in each individual 
colorectal cancer cell line was compared to the normal colon epithelial cell line. 
 We confirmed miRNA expression of these five miRNAs to be significantly up-
regulated in all colorectal cancer cell lines compared to the normal colon epithelial cell 
line (Table 6). The Dukes’ C CRC cell line had the largest up-regulation of all five miR-
200 family members compared to the normal colon epithelial cell line than any of the 





Table 2. Significantly Dysregulated miRNAs in Colorectal Cancer Cell Lines Compared to a Normal Colon Epithelial Cell Line 
Cell Line Comparison vs. Normal 
Colon Epithelium 




Up-Regulated (n) Downregulated (n) 
Localized Stage Cancer  
(Dukes’ A SW1116 and B SW480) 190 36 154 
Metastatic Stage Cancer  
(Dukes’ C HT-29 and D T84) 231 39 192 
 
*





Table 3. The Most Significantly Up-regulated and Downregulated miRNAs in Localized Colorectal Cancer Cell Lines (Dukes’ A 
SW1116 and B SW480) Compared to the Normal Colon Epithelial Cell Line (CCD 841) and Corresponding Fold Change 
Up-regulated Downregulated 
miRNA Fold Change p-value miRNA Fold Change p-value 
miR-200a 18830 <0.0001 miR-143 -4545 <0.0001 
miR-429 11414 <0.0001 miR-329 -5000 <0.0001 
miR-203 7406 <0.0001 miR-654-3p -5556 <0.0001 
miR-135b 6566 <0.0001 miR-134 -7143 <0.0001 
miR-141 6478 <0.0001 miR-193a-5p -10000 <0.0001 
miR-200b 3756 <0.0001 miR-214 -10000 <0.0001 
miR-95 3380 <0.0001 miR-541 -11111 <0.0001 
miR-200c 2688 <0.0001 miR-485-3p -16667 <0.0001 
miR-518f 1289 0.041 miR-485-5p -16667 <0.0001 
miR-9 1165 <0.0001 miR-296 -25000 <0.0001 
miR-182 1129 <0.0001 miR-409-5p -33333 <0.0001 
miR-183 546 <0.0001 miR-654 -33333 <0.0001 
miR-375 532 <0.0001 miR-379 -33333 <0.0001 
miR-302a 368 0.003 miR-199a -50000 <0.0001 
miR-142-3p 348 0.008 miR-410 -50000 <0.0001 
miR-372 272 0.045 miR-493 -50000 <0.0001 
miR-96 151 <0.0001 miR-495 -50000 <0.0001 
miR-192 124 0.009 miR-127 -100000 <0.0001 
miR-135a 119 <0.0001 miR-369-5p -100000 <0.0001 





Table 4. The Most Significantly Up-regulated and Downregulated miRNAs in Metastatic Colorectal Cancer Cell Lines (Dukes’ C HT-
29 and D T84) Compared to the Normal Colon Epithelial Cell Line (CCD 841) and Corresponding Fold Change 
Up-regulated Downregulated 
miRNA Fold Change p-value miRNA Fold Change p-value 
miR-200a 35668 <0.0001 miR-486-3p -250 <0.0001 
miR-429 30476 <0.0001 miR-504 -250 0.002 
miR-200b 8862 <0.0001 miR-34c -333 <0.0001 
miR-141 6531 <0.0001 miR-542-3p -333 <0.0001 
miR-203 6347 <0.0001 miR-99a -333 <0.0001 
miR-200c 4171 <0.0001 miR-100 -500 <0.0001 
miR-135b 3377 <0.0001 miR-424 -500 0.002 
miR-375 2490 <0.0001 miR-450a -500 0.001 
miR-183 759 <0.0001 miR-541 -500 <0.0001 
miR-182 754 <0.0001 miR-130a -1000 <0.0001 
miR-142-3p 577 0.019 miR-199a -1000 <0.0001 
miR-215 454 0.001 miR-299-5p -1000 0.001 
miR-196b 407 <0.0001 miR-323-3p -1000 <0.0001 
miR-192 296 <0.0001 miR-369-3p -1000 <0.0001 
miR-194 179 <0.0001 miR-409-5p -1000 <0.0001 
miR-96 109 0.001 miR-485-3p -1000 <0.0001 
miR-582-5p 95 <0.0001 miR-485-5p -1000 <0.0001 
miR-95 88 0.022 miR-654 -1000 <0.0001 
miR-135a 77 <0.0001 miR-654-3p -1000 <0.0001 




Figure 11. Waterfall Plot of the Significantly Dysregulated miRNAs in Localized 
Colorectal Cancer Cell Lines (Dukes’ A SW1116 and B SW480) as Compared to the 






Figure 12. Waterfall Plot of the Significantly Dysregulated miRNAs in Metastatic 
Colorectal Cancer Cell Lines (Dukes’ C HT-29 and D T84) as Compared to the Normal 








Table 5. miR-200 Family Expression in Colorectal Cancer Cell Line Screening 
Cell Line Comparison vs. Normal 
Colon Epithelium 
miRNA Fold Change p-value 
Localized Stage Cancer  
(Dukes’ A SW1116 and B SW480) 
miR-200a 18830 <0.0001 
miR-200b 3756 <0.0001 
miR-200c 2688 <0.0001 
miR-141 6478 <0.0001 
miR-429 11414 <0.0001 
Metastatic Stage Cancer  
(Dukes’ C HT-29 and D T84) 
miR-200a 35668 <0.0001 
miR-200b 8862 <0.0001 
miR-200c 4171 <0.0001 
miR-141 6531 <0.0001 






Table 6. Single Assay miRNA Validation of miR-200 Family in Colorectal Cancer Cell Lines Compared to a Normal Colon Epithelial 
Cell Line (CCD 841) 
 






















miR-200a 1541 <0.0001 1186 <0.0001 15104 <0.0001 1410 <0.0001 
miR-200b 4238 <0.0001 3989 <0.0001 22039 <0.0001 3340 <0.0001 
miR-200c 3303 <0.0001 3752 <0.0001 7323 <0.0001 5216 <0.0001 
miR-141 23207 <0.0001 27067 <0.0001 35026 <0.0001 19135 <0.0001 






c) Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA) (Qiagen, Hilden, Germany) is an intuitive web-
based application for quickly analyzing and accurately interpreting the biological 
meaning in your genomic data. It allows for the input of sequencing, Real-Time PCR, 
and microarray data. Among many of its features, IPA is able to combine filtering tools 
and microRNA-mRNA content to provide insight into the biological effects of identified 
miRNAs. It is also identifies genes that are shown to be activated in a pathological 
condition and highlights canonical and non-canonical pathways associated with 
biological processes. IPA allows for identification of promising targets for therapeutic 
development. 
 From our microarray screening, IPA was able to identify miRNAs and the 
associated pathways they targeted, relevant to our data. The signaling pathway most 
closely linked to the colorectal cancer cell line screening data was the ERK MAPK 
pathway as previously described. miR-200b and miR-141 were identified as being 
strongly upregulated within this pathway (Figure 13). 
 We used a miRNA target prediction program to identify targets associated to 
these dysregulated miRNAs. miRTarBase is a database of miRNA-target interactions that 
are experimentally validated by reporter assay, western blot, microarray and next-
generation sequencing experiments. It provides up to date information and combines the 
largest amount of validated miRNA-target interactions by comparing content from other 
similar target databases. miRTarBase identified all five miRNAs (miR-200a, miR-200b, 




























































miRTarBase is available at http://miRTarBase.mbc.nctu.edu.tw/ 
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significantly dysregulated in our colorectal cancer cell lines compared to normal colon 
epithelium to have multiple targets. Of interest, all five of these miRNAs were validated 
targets of the same gene, Ras associated domain-containing protein 2 (RASFF2) (Figure 
14 & 15). 
d) microRNA-200 Family 
The miR-200 family consists of five members, miR-200a, miR-200b, miR-200c, 
miR-141, and miR-429. They form two clusters located in two different genomic regions. 
Cluster 1, miR-200a, miR-200b, and miR-429, is located on chromosome 1, whereas 
miR-200c, and miR-141 is located on chromosome 12. The seed sequence of a miRNA is 
the second to eighth nucleotide region at the 5’ end of the mature miRNA, that generates 
the specificity of each miRNA to its target mRNA. Additionally, the miR-200 family can 
be divided into two functional groups, based on their seed sequences. Functional group 1, 
miR-200b, miR-200c, and miR-429, and functional group 2, miR-200a and miR-141, 
with each functional group sharing the same seed sequence (Figure 16). The miR-200 
family has been widely investigated in regards to its role in cancer, and is known to be 
well associated with epithelial to mesenchymal transition (EMT).  
EMT is the process by which epithelial cells lose cell polarity, cell to cell 
adhesion, and gain migratory and invasive properties.(123) These cells transform into 
mesenchymal stem cells (Figure 17). EMT is essential for numerous development 
processes, and plays a role in wound healing, fibrosis, and cancer. EMT was recognized 
as a feature of embryogenesis, and its reverse process, mesenchymal-epithelial transition 
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Figure 16. Genomic Location of miR-200 Family and Seed Sequence of Functional 








miR-200a, miR-200b and miR-429 located on Chromosome 1 
miR-200c and miR-141 located on Chromosome 12 
Red = Functional group 1, Blue = Functional group 2. The two functional groups only 









Jurmeister S, Uhlmann S, Sahin Ö. MIR200C (microRNA 200c). Atlas Genet Cytogenet 
Oncol Haematol. 2012;16(2):92-99   
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Figure 17. Epithelial to Mesenchymal Transition  
Epithelial to Mesenchymal Cell Transition – loss of cell adhesion leads to constriction 










Thiery JP, Sleeman JP. (2006). "Complex networks orchestrate epithelial-mesenchymal 
transitions". Nature Reviews Molecular Cell Biology 7: 131–142  
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(MET), is critical for development of many tissues and organs in the developing embryo. 
Epithelial cells are stationary, expressing high levels of E-cadherin, whereas 
mesenchymal cells are able to migrate and invade and express N-cadherin, fibronectin, 
and vimentin. The loss of E-cadherin is considered a fundamental event in EMT, either 
direct or indirect. Direct loss occurs when Zinc finger E-box-binding homeobox (ZEB) 1 
/ ZEB2 binds to E-cadherin and causes repression of transcription. Several signaling 
pathways may induce EMT. TGF-β activates the expression of ZEB and SNAIL to 
regulate EMT in cancer. The p53 tumor suppressor inhibits EMT by activating the 
expression of various miRNAs. EMT is involved in cancer progression and metastasis. 
The loss of E-cadherin causes cells to lose adhesion which break through the basement 
membrane, increasing the invasive properties of cells.  
Differential expression of the miR-200 family is involved in initiation and 
progression of malignant transformation. The miR-200 family regulates epithelial to 
mesenchymal transition by targeting ZEB1 and ZEB2.(124) Low miR-200 levels were 
identified in breast cancer cells that underwent EMT in response to TGF-β, conversely, 
increased miR-200 expression prevented TGF- β induced EMT. Induction of EMT 
occurred with inhibition of the miR-200 family and subsequent upregulation of ZEB1 and 
ZEB2. Hence, it was concluded that downregulation of the miR-200 family was an 
important step in tumor progression. Another study identified miR-200 members were 
downregulated in colorectal adenocarcinomas that had invaded beyond the basement 
membrane, however; lymph node metastases showed high expression of miR-200. On the 
other hand, colorectal adenomas and adenocarcinomas with intact basement membranes 
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had high expression of miR-200 members. Their conclusions supported the involvement 
of the miR-200 family in EMT and cancer progression.(125) 
Significant work has been performed investigating the role of the miR-200 family 
in many processes. The miR-200 family has been implicated in cell transformation and 
tumorigenesis, cancer metastasis, tumor growth, angiogenesis, invasion and migration, 
tumor cell survival in circulation, intra and extravasation, and as a potential diagnostic 
and prognostic tool.(126) The majority of research with the miR-200 family focuses on 
EMT of cancer cells where dysregulation is considered to exhibit tumor suppressive 
behavior by blocking EMT. However; increased levels of miR-200c, in particular, in 
various cancers contradicts the tumor suppressive role of this miRNA.(127) miR-200 
family levels are enriched in epithelial tissues. This is supported by lower expression of 
miR-200c in metastatic colorectal cancer cell lines, SW620, LOVO, and RKO compared 
to epithelial colorectal cancer cell lines, SW480, HT-29, and T84.(128-130) Multiple 
studies have also confirmed the findings of enhanced levels of miR-200c in CRC tissue 
compared to healthy control tissue.(131-133) Overexpression of miR-200c induced cell 
proliferation in SW620 CRC cell lines (129), whereas another study observed reduced 
proliferation in SW480 and SW620 CRC cell lines.(130) Downregulation of miR-200c in 
HT-29 and T84 CRC cell lines increased cell apoptosis and decreased tumor 
growth.(134)  
Since the data regarding the miR-200 family is contradictory more work is needed 
to gain a better understanding on the role this family plays in cancer, and to understand 
the mechanisms involved in cancer initiation and progression. Much of what we already 
know relates to the individual miRNAs, miR-200b and miR-200c, hence more research 
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needs to be conducted on the remaining members, miR-200a, miR-141, and miR-429. It 
is important to be able to distinguish which miR-200 family members act as tumor 
suppressors and which may promote cancer progression. 
e) Ras Associated Domain-Containing Protein (RASSF2) 
 The Ras family of onco-proteins regulates a wide range of biological processes by 
interacting with a variety of effector proteins, the most well characterized being BRAF 
and PI3K. Activated forms of Ras are associated with oncogenesis usually due to 
mutation, however; they can also exhibit growth-antagonistic effects such as senescence, 
cell cycle arrest, differentiation, and apoptosis.(135, 136)  Previously, a novel Ras 
effector, RASSF1, was identified as a mediator of apoptosis and cell cycle arrest, with the 
protein displaying many properties associated with tumor suppressors.(137) Ras 
Associated Domain-Containing Protein (RASSF2) is one of ten in the RASSF family of 
proteins encoded by RASSF genes 1-10, and subsequent to the discovery of RASSF1, 
was identified as a novel K-Ras specific effector and tumor suppressor.(138) RASSF2 
was found to be a negative regulator of Ras, by binding directly to K-Ras in a GTP-
dependent manner via the Ras effector domain. The interaction of RASSF2 and Ras 
proteins was found to be specific to K-Ras, rather than H-Ras or N-Ras. RASSF2 was 
found to promote apoptosis and cell-cycle arrest, and was frequently downregulated in 
human lung cancer cell lines. In addition, overexpression of RASSF2 inhibited growth of 
lung cancer cells suggesting that RASSF2 shared the properties, similar to other 
identified RASSF proteins, in being a potential tumor suppressor. Other groups 
confirmed the findings that RASSF2 and K-Ras form an endogenous complex, and 
demonstrated tumor suppressor properties by the loss of expression causing enhanced cell 
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proliferation and invasion in cell lines.(139) RASSF2 is silenced by aberrant DNA 
promoter methylation in CRC, and expression has been found to be frequently 
downregulated in CRC cell lines. This is supported by studies investigating the properties 
and methylation status of RASSF2 in CRC tissue and colorectal adenoma samples. 
Multiple studies have reported the methylation of RASSF2 between 42% - 73% in CRC 
samples, and one study reported the methylation status of RASSF2 of 100% in colorectal 
adenoma samples.(140-142)  
It is widely accepted that RASSF members belong to a recently identified family 
of tumor suppressor Ras effectors for which epigenetic silencing by promoter 
methylation has been shown to occur throughout the progression of cancer including 
CRC.(143-145) Clarification of cellular mechanisms that regulate the signaling pathways 
RASSFs are involved in is further needed, however; RASSFs may have the potential to 







HYPOTHESIS, SPECIFIC AIMS, AND EXPERIMENTAL PLAN 
 
a) Key Objective 
 To investigate the role of the miR-200 family on the tumor suppressor RASSF2, 
and determine the effect it has on activity within the mitogen-activated protein kinase 
(MAPK) signaling pathway, in a normal colon epithelial (CCD 841) cell line and a 
Dukes’ C (HT-29) colorectal cancer cell line.  
b) Hypothesis 
 The MAPK pathway is a major regulator of cell proliferation and is frequently 
mutated in CRC. miRNAs from the miR-200 family (miR-200a, miR-200b, miR-200c, 
miR-141, miR-429) have been shown to promote cell proliferation when transfected into 
various cell lines. It has been shown that the miR-200 family targets RASSF2, a negative 
regulator of K-Ras, however; the relationship between miR-200, RASSF2, K-Ras, and 
subsequent activity within the MAPK pathway in colorectal cancer, has not yet been fully 
described. 
We hypothesize that miR-200 family expression differs between normal colon 
epithelial (CCD 841) and Dukes’ C (HT-29) colorectal cancer cells and manipulation of 
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their expression could modify cancer cell behavior. In doing so, the miR-200 family may 
have the potential to be developed as a therapeutic intervention in CRC (Figure 18). 
c) Specific Aims 
1: To determine the expression of the miR-200 family and RASSF2 in both a 
normal colon epithelial (CCD 841) and a sporadic Dukes’ C (HT-29) colorectal 
cancer cell line. 
2: To examine the gain and loss of function of the miR-200 family and the 
resulting effect on RASSF2 expression, in both a normal colon epithelial (CCD 
841) and a sporadic Dukes’ C (HT-29) colorectal cancer cell line, respectively.  
3: To demonstrate the effect of the miR-200 family on MAPK signaling pathway 
activity as measured by activation of pathway proteins and resulting cell 
proliferation. 
d) Experimental Plan  
 The overall goal of this project is to investigate the role of the miR-200 family in 
relation to activity of the MAPK signaling pathway and effect upon cell proliferation 
mediated via the tumor suppressor RASSF2. We will first evaluate expression of the 
miR-200 family in a normal colon epithelial (CCD 841) cell line and compare it to the 
expression in Dukes’ stage CRC cell lines. If a difference is observed, RASSF2, a target 
of the miR-200 family, will be investigated, along with the associated signaling pathway. 
Secondly, the miR-200 family will be manipulated using miRNA mimics and antagomirs 
to increase or decrease their expression in the respective cell lines, and RASSF2 mRNA 
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and protein expression then measured. Finally, MAPK signaling pathway activation will 
be assessed and cell proliferation, the major resulting functional outcome, will be 
measured in both normal colon epithelial and Dukes’ C CRC cells. We will thus 
determine whether manipulation of the miR-200 family can influence CRC cell behavior 




Figure 18. Hypothesis Overview. 











MATERIALS AND METHODS 
 
a. Cell Lines 
 For the purposes of this study, five cell lines representing the four stages of 
modified Dukes’ A to D colorectal cancer and normal colon epithelium were acquired 
from American Type Culture Collection (ATCC®, Manassas, Virginia). Sporadic 
colorectal cancer cell lines were selected for study. KRAS mutation and microsatellite 
instability status is shown in Table 7. Cells were cryopreserved in liquid nitrogen at -
80˚C until being initiated and allowed to grow for future testing. All cell lines were 
adherent in nature, cultured in cell culture flasks and incubated at 37˚C and 5% CO2. 
Cells were grown to 70-90% confluence before being harvested for further studies.  
1. CCD 841 CoN (ATCC® CRL-1790™) 
Normal epithelial colon cells harvested from a human female fetus at 21 weeks 
gestation period, and cultured in Eagle’s Minimum Essential Medium (EMEM) 
with 15% fetal bovine serum (FBS), and supplemented with a 0.5% mixture of 
penicillin, streptomycin, amphotericin B, and 0.5% L-glutamine (Figure 19). 
 60 
 
2. SW1116 (ATCC® CCL-233™) 
Dukes’ A, grade III, primary colorectal adenocarcinoma epithelial cells were 
harvested from a 73 year-old man. Cells were cultured in Dulbecco’s Modified 
Eagle (DMEM) medium with 10% FBS, and supplemented with a 0.5% mixture 
of penicillin, streptomycin, amphotericin B, and 0.5% L-glutamine. This cell line 
was microsatellite stable and positive for expression of mutated K-Ras oncogene 
(Figure 20).  
3. SW480 (ATCC® CCL-228™) 
Dukes’ B, primary colorectal adenocarcinoma epithelial cells were harvested from 
a 50 year-old man. Cells were cultured in Dulbecco’s Modified Eagle (DMEM) 
medium with 10% FBS, and supplemented with a 0.5% mixture of penicillin, 
streptomycin, amphotericin B, and 0.5% L-glutamine. This cell line was 
microsatellite stable and positive for expression of K-Ras oncogene with a 
mutation in codon 12 of the ras oncogene (Figure 21).  
4. HT-29 (ATCC® HTB-38™) 
Dukes’ C, primary colorectal adenocarcinoma epithelial cells were harvested from 
a 44 year-old woman. The cells were cultured in McCoy’s 5A medium with 10% 
FBS, and supplemented with a 0.5% mixture of penicillin, streptomycin, 
amphotericin B, and 0.5% L-glutamine. This cell line was microsatellite stable 
and positive for expression of wild type K-Ras oncogene (Figure 22).  
5. T84 (ATCC® CCL-248™) 
Dukes’ D, secondary colorectal adenocarcinoma epithelial cells derived from a 
metastatic lung site were harvested from a 72 year-old man. The cells were 
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cultured in Dulbecco’s Modified Eagle’s medium and Ham’s F-12 (DMEM/F-12) 
with 10% FBS, and supplemented with a 0.5% mixture of penicillin, 
streptomycin, amphotericin B, and 0.5% L-glutamine. This cell line was 
microsatellite stable and positive for expression of mutated K-Ras oncogene 
(Figure 23).  
b. Maintenance of Cell Lines  
 All cell lines were incubated at 37˚C and 5% CO2 until being transferred to a 
sterile cell culture hood for subsequent use. Gloved hands were cleansed with 70% 
ethanol (EtOH) prior to handling and transferring cell culture flasks from the incubator to 
the hood. All other items transferred into the culture hood were cleansed with 70% EtOH 
prior to use. Once cells were returned to the incubator, the cell culture hood was cleansed 
with 70% EtOH to maintain sterility. Only one cell line at a time was used in the culture 
hood to avoid cross contamination. 
1. Establishment of Cell Lines from Cryopreservation 
Cell line specific medium was removed from refrigeration and warmed to room 
temperature in a water bath. For each cell line, 8mL of culture medium was added to a 
15mL tube. Another 8mLs of culture medium was then added to a 25cm3 flask. Care was 
taken not to wet the flask neck in order to avoid contamination. The cell line name, 
medium, %FBS, passage number of cells, date and initials were written on each flask. 
Each cryopreserved cell line vial was removed from liquid nitrogen and immediately 
thawed in a 37˚C water bath. The O-ring and cap were suspended above the water to 
avoid contamination. Once thawed, the contents were transferred to the 15mL tube using 
a 1000μL pipette. This tube was centrifuged at 830 rpm, at 37˚C for 7 minutes, until a 
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cell pellet was formed. The medium was then aspirated and discarded and the cell pellet 
re-suspended with 1mL culture medium. This re-suspended cell mixture was then 
transferred to the labelled 25cm3 culture flask. Cells were visualized within the culture 
flask under a microscope before transferring to the incubator for growth.  
 
2. Sub-culturing and Splitting of Cells 
Cells were visualized daily under a microscope (10X) to monitor growth. Once 
the cells were deemed to be 70 – 90% confluent they were divided. Appropriate culture 
medium and a 6mL aliquot of trypsin-ethylenediaminetetraacetic acid (EDTA) were 
warmed and thawed, respectively, in a water-bath to room temperature before being 
cleansed with 70% EtOH and placed in the culture hood. The medium was decanted into 
a waste beaker and 6mL of trypsin was added to the flask and was gently rocked back 
and forth before being placed back into the incubator for 5 minutes to aid trypsinization. 
During this time, 18mL of the appropriate cell line culture medium was added to a new 
75cm3 flask(s). After 5 minutes, cells were removed from the incubator and observed 
under an inverted microscope in order to confirm that the cells were no longer adhered to 
the bottom of the flask. Once this was confirmed, the flask was returned to the culture 
hood and 9mL culture medium was added to the flask to stop trypsinization and multiple 
washings performed to ensure cell collection. Following this, the cell suspension was 
transferred to a new 15mL tube and centrifuged at 830rpm for 7 minutes. The supernatant 
was discarded and the remaining cell pellet was re-suspended in 1mL medium using a 
micropipette tip to achieve single-cell suspension. An additional 4mL medium was then 




Table 7. Characteristics of Cell Lines 




 Medium (%FBS) 











Colon Stable Mutated WT WT 1:3 – 1:6 





Colon Stable Mutated WT WT 1:2 – 1:8 





Distal Colon Stable WT Mutated WT 1:3 – 1:8 







Stable Mutated WT WT 1:2 – 1:4 
DMEM/F-12 (10)  
 
*












The CCD 841 cells are epithelial-like cells that grow as a flattened and disorganized layer in culture. Cells are long and epithelial-
like with long thin processes. At low density cells will be relatively sparse and at higher densities cells may begin to overlap one 
another. 
 























Figure 21. Morphology and Growth of Cell Lines SW480 – Dukes’ B CRC 
At lower densities, cells will appear more rounded and may appear in small clumps of a few cells. At high densities, the cells will take 
on a more polygonal shape with defined borders between cells. 
 
















The cells attach in patches as three-dimensional aggregates and as they divide and grow they flatten into an epithelial cell monolayer. 
At lower densities, cells will attach as single cells and will be spread apart. Cells appear rounded. At higher densities, many 
independent "islands" of growing cells come together leading to the large cell mass seen in the higher density picture 

















Similar to HT-29. At lower densities, small islands of cells will be growing sparsely around the flask. At higher densities, these cell 
"islands" will join together to form the large cell mass seen in the high density picture 
T84 (ATCC® CCL-248™) is available at: www.atcc.org  
 69 
 
Cell counting was performed manually and cells stained with tryphan blue using a 
1:5 dilution by diluting 10μL of the cell solution to 40μL before sampling a 10μL aliquot 
for counting using a hemocytometer. Total cell count was determined by the following 
formula: 
Cell Count x Dilution Factor x 10
4
 x Volume 
Following this, cells were either plated at pre-determined amounts for use in experiments 
or sub-cultivated to allow for further growth. 
3. Freezing of Cells 
 Cells were split and counted as described above. Cells selected for 
cryopreservation were at low passage numbers (<10) and viable. Cryo-media was created 
using a solution of the cells respective media and dimethylsulfoxide (DMSO) so that the 
final volume contained 5% DMSO. Cells were then added to the solution so that the 
concentration of cells was 4 x 106 cells/2mL of cryo-media. 2mL of this suspension was 
labeled and stored in a sterile cryogenic vial (Corning Inc.). These cryogenic vials were 
then stored in a Cryo 1°C Freezing Container (NALGENE) ethanol bath and placed in a -
80°C storage freezer in order to achieve a -1°C/min cooling rate. After 24 hours of 
cooling in the ethanol bath, these cryogenic vials were transferred to a liquid nitrogen 
storage container for storage until needed. 
c.  Harvesting Cells for RNA 
 Cells were plated at 250,000 cells/2mL in a 6-well plate and allowed to grow to 
confluence. Once confluent, the medium was carefully removed from each well and 
discarded. 300μL of cell lysis buffer was added to each well. After 5 minutes, the bottom 
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of each well was scraped using a pipette tip and the resulting product was collected in 
labelled freeze tubes and stored at -80˚C until needed. 
d.  Harvesting Cells for Protein 
 Cells were plated at 250,000 cells/2mL in a 6-well plate and allowed to grow to 
confluence. For every 6-well plate, 1μL of protease and 1μL of phosphatase inhibitors 
were supplemented to 1mL of radio immune-precipitation assay (RIPA) buffer. The 
medium was carefully removed from each well and 150μL of RIPA / protease & 
phosphatase mix was added. The bottom of each well was scraped using the rubber 
plunger from a syringe, the sample was collected and stored at -80˚C in pre-labeled 
freeze tubes or immediately processed for protein quantification. 
e. Total RNA Isolation 
 Isolation of total RNA from cell lysates was performed using the Ambion® 
miRVana miRNA Isolation Kit (Life Technologies, Carlsbad, CA). A 1:10 concentration 
of homogenate was added to each cell sample and incubated on ice for 10 minutes. Equal 
volumes of Acid-Phenol-Chloroform were added to the lysate. Samples were vortexed 
and centrifuged for 5 minutes at 10,000g. Careful removal of the aqueous top phase to a 
new tube was then performed to avoid contamination and maintain purity. The total 
volume removed was recorded and 1.25 times 100% EtOH was added to the lysate. After 
mixing, 700μL sample was added to a new spin column. This was centrifuged for 15 
seconds at 10,000g and flow-through was discarded. 700μL of Wash Solution 1 was 
added to each spin column, followed by centrifugation at 10,000g for 10 seconds before 
the flow-through was discarded. This was followed by the addition of 500μL of Wash 
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Solution 2 and centrifugation at 10,000g for 10 seconds. The same procedure is then 
performed for Wash Solution 3. The spin column is removed and the sample placed into a 
new tube, which is then centrifuged for 1 minute at 10,000g to remove excess liquid. 
Finally, 40μL of pre-heated elution solution (95˚C) was added to the filter in the spin 
column and centrifuged for 30 seconds at maximum speed. Quantitation of total RNA 
quantity and quality was then determined using a Nanodrop 2000 spectrophotometer 
(ThermoFisher Scientific®, Middlesex, MA). Samples can be contaminated with other 
molecules, such as proteins or organic compounds. To assess the nucleic acid quality of 
our samples we measure the ratio of absorbance at 260nm and at 280nm (A260/280). For 
good quality RNA, the A260/280 should be ~1.8-2.2. The total RNA concentration and 
quality of our samples are shown in Tables 8 & 9.  
f. microRNA Screening of Cell Lines 
 For each cell line, the expression levels of 384 miRNAs were examined using 
TaqMan® Low Density Array (TLDA) human miRNA card A following the 
manufacturers protocol (Life Technologies, Carlsbad, CA). Each cell line was screened 
for expression of dysregulated miRNA four times.  
Complementary DNA (cDNA) was generated from total RNA samples using the 
TaqMan® miRNA Reverse Transcription kit (Life Technologies, Carlsbad, CA). Reverse 
transcription (RT) total reaction volume for each sample was 75μL, consisting of 45μL 






Table 8. Total RNA Concentration and Purity of Normal Colon Epithelial and Dukes’ Colorectal Cancer Cell Lysates used for miRNA 
Cell Line Screening. 
 
Cell Line 
RNA Concentration (ng/μL) RNA Purity (A260/280) 
Replicate (no.) Replicate (no.) 
1 2 3 4 1 2 3 4 
Normal Colon Epithelium CCD 841 137 147 42 34 2.08 2.04 2.02 2.09 
Dukes’ A CRC (SW1116) 108 451 - - 2.06 2.18 - - 
Dukes’ B CRC (SW480) 247 649 - - 2.08 2.11 - - 
Dukes’ C CRC (HT-29) 496 356 - - 2.11 2.09 - - 







Table 9. Total RNA Concentration and Purity following Transfection with miR-200 Family Mimics and Antagomirs. 
Cell Line 
RNA Concentration (ng/μL) RNA Purity (A260/280) 
Replicate (no.) Replicate (no.) 








miR-200a 147 176 161 263 126 1.79 1.79 1.75 1.79 1.76 
miR-200b 128 99 263 184 167 1.76 1.71 1.76 1.71 1.71 
miR-200c 132 189 130 256 83 1.80 1.72 1.77 1.76 1.97 
miR-141 185 212 149 90 192 1.76 1.77 1.72 1.99 1.74 
miR-429 105 153 193 132 344 1.88 1.68 1.71 1.69 1.83 
miR-200 All* 181 92 148 175 210 1.73 1.73 1.84 1.70 1.70 







miR-200a 156 133 146 134 114 2.05 2.11 2.08 2.11 2.07 
miR-200b 66 141 130 82 121 2.00 2.11 2.02 2.10 2.10 
miR-200c 158 116 138 98 123 2.00 2.07 2.10 2.08 2.10 
miR-141 202 148 148 204 183 2.10 2.04 2.02 2.06 2.06 
miR-429 144 94 190 174 211 2.04 2.03 2.04 2.04 2.09 
miR-200 All* 288 194 198 257 294 2.09 2.08 2.07 2.08 2.09 
A-†† 214 182 192 198 103 2.08 2.07 2.09 2.09 2.05 
 
* Combination of all five miRNA mimics or antagomirs together (125pmol total vs. 25pmol for each individual miRNA) 
† Mimic Negative Control 




Component Volume (μL) per 75μL Reaction† 
Megaplex™ Reverse Transcription Human Pool 
A v.2.1 Primers 
9.00 
100nM dNTPs (with dTTP) 2.25 
MultiScribe™ Reverse Transcriptase, 50U/μL 16.88 
10X Reverse Transcription Buffer 9.00 
25mM MgCl2 Solution 10.20 
RNase Inhibitor, 20U/ μL 1.12 
Total 48.45 
† Inclusive of 12.5% excess to compensate for pipetting loss  
Once complete, the sample was vortexed, centrifuged to remove air bubbles and run on a 
pre-set thermal cycler program. Samples were either used immediately or stored at -20˚C 
until further use.  
Each TLDA card comprises of 8 fill reservoirs with a fill port on the left and a 
vent port on the right. For each sample, a master mix of 900μL was prepared in a 1.5mL 
microcentrifuge tube, vortexed and centrifuged to eliminate air bubbles. The master mix 
consisted of the following: 
Component Volume (μL) per TLDA Card
†
 
TaqMan® Universal Master Mix II, no 
UNG 
450 
Nuclease-free water 375 




†Inclusive of 12.5% excess to compensate for pipetting loss  
The TaqMan Array card was removed from its packaging and warmed to room 
temperature with minimal exposure to sunlight and placed on a lab bench, with the foil 
side down. Each reservoir was filled with 100μL of sample-specific PCR mix made from 
a single cDNA sample. The micropipette was held at an angled position to dispense the 
sample and care was taken not to displace the reaction mix outside of the reservoir or 
introduce air bubbles. After the reservoir had been filled with PCR reaction mix, the card 
was centrifuged using a Sorvall® centrifuge bucket and holder for 1 minute at 1200rpm. 
Confirmation that filling of the TaqMan card was complete was observed by a consistent 
reduction in the fluid within each reservoir. The TaqMan Array card was sealed using a 
TaqMan® Array Micro Fluidic Card Sealer, removed and quantitative real-time 
polymerase chain reaction (qRT-PCR) performed using a ViiA™ 7 Real-Time PCR 
System (ThermoFisher Scientific®, Middlesex, MA).  
Expression levels of each individual miRNA were normalized to RNU6 
(endogenous internal reference gene), using a cycle threshold (Ct) of 0.2, in order to 
calculate ΔCt values for analysis using the comparative ΔCt method. miRNA expression 
of each CRC cell line was compared to the miRNA expression of the normal colon 
epithelium cell line. 
g. microRNA Single Assay Validation 
 For miRNA single assay quantification, total RNA was converted to cDNA using 
the TaqMan® miRNA Reverse Transcription kit and specific TaqMan® miRNA primers 
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for the miR-200 family and RNU6 (Life Technologies, Carlsbad, CA). Specific 
TaqMan® probes for each miRNA were then used to bind to complementary sequences 
on target cDNA during qRT-PCR (Life Technologies, Carlsbad, CA). Reverse 
transcription (RT) total reaction volume for each sample was 15μL, consisting of 7μL 
master mix, 3μL TaqMan® miRNA primer, and 5μL RNA (2ng/μL) sample. The RT 
master mix was made using the following: 
Component Volume (μL) per 15μL reaction† 
100nM dNTPs (with dTTP) 0.17 
MultiScribe™ Reverse Transcriptase, 50U/μL 1.13 
10X Reverse Transcription Buffer 1.69 
RNase Inhibitor, 20U/ μL 0.21 
Nuclease-free water 4.68 
TaqMan® miRNA primer 3.38 
Total 11.25 
† Inclusive of 12.5% excess to compensate for pipetting loss  
Once the master mix for each miRNA was made, the contents were gently mixed and 
centrifuged to bring the solution to the bottom of the tube, and then placed on ice until the 
RT reaction was ready to be run. 10μL of each RT master mix was added to wells in a 
96-well reaction plate followed by 5μL of RNA sample. The reaction plate was then 
sealed, vortexed, and centrifuged before running on a pre-set thermal cycler program. 
Once complete, the cDNA was either used immediately to run qRT-PCR or stored at -
20˚C until further use. 
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Nucleic acid quantification was performed using a Step-One Plus qRT-PCR 
system (Life Technologies, Carlsbad, CA). A 10μL qRT-PCR reaction volume was 
performed and each reaction was performed in duplicate. Similar to the RT reaction, a 
master mix cocktail for qRT-PCR for each miRNA was made as follows: 
Component 




TaqMan® MicroRNA Assay (20X) 0.56 
TaqMan® Universal Master Mix II, no UNG 5.63 
Nuclease-free water 3.57 
Product from RT reaction (Minimum 1:15 Dilution) 1.33 
Total 11.08 
† Inclusive of 12.5% excess to compensate for pipetting loss 
Once made, the master mix was gently mixed and centrifuged to bring solution to 
the bottom of the tube. 8.67μL PCR master mix was dispensed into each well on a 96-
well plate followed by 1.33μL of the RT product. Once loaded, the plate was sealed, 
vortexed and centrifuged to spin down the contents and eliminate air bubbles. The 
reaction plate was then run on a pre-set thermal cycler program using the Step-One Plus 
qRT-PCR machine.  
The levels of each individual miR-200 family member were normalized to RNU6, 
using a Ct threshold of 0.1, in order to calculate ΔCt values for analysis using the 
comparative ΔCt method. All reactions were completed in duplicate. Analysis was 
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performed for expression of individual miR-200 family members for each CRC cell line 
as compared to that seen in the normal colon epithelium cell line. 
h. messengerRNA (mRNA) Quantification 
  For mRNA quantification, total RNA was converted to cDNA using a High 
Capacity cDNA Reverse Transcription kit (Life Technologies, Carlsbad, CA) with 
random nucleotide primers. Preparation of a 2X RT master mix per 20μL reaction was 
made as follows: 
Component Volume (μL) per 20-μL reaction 
10X RT Buffer 2.00 
25X dNTP Mix (100mM) 0.80 
10X RT Random Primers 2.00 
MultiScribe™ Reverse Transcriptase 1.00 
RNase Inhibitor 1.00 
Nuclease-free water 3.20 
Total 10.00 
 
10μL of the 2X RT master mix was pipetted into each well of a 96-well reaction 
plate followed by 10μL of RNA sample (2ng/μL) and mixed. The plate was sealed, 
vortexed and centrifuged to spin down the contents and eliminate air bubbles. The plate 
was placed on ice until ready to load into and run the thermal cycler on a pre-set program. 
On completion, the cDNA RT plate was either used immediately to run qRT-PCR or 
stored at -20˚C until further use. 
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 Specific TaqMan® probes for RASSF2 and 18S (endogenous internal reference 
gene) were used during qRT-PCR and all reactions were completed in duplicate. The 
total number of PCR reactions was determined and the reaction mix was made as follows: 
Component Volume (μL) per reaction 
TaqMan® Fast Advanced Master Mix (2X) 5.00 
TaqMan® Gene Expression Assay (20X) 0.50 
Nuclease-free water 3.50 
Total 9.00 
 
Nine μL PCR reaction mix and 1μL cDNA was added to each well, mixed, and 
covered with optical adhesive film and sealed. The plate was briefly centrifuged to spin 
down the contents and eliminate air bubbles.  Nucleic acid quantification was performed 
using a Step-One Plus qRT-PCR system (Life Technologies, Carlsbad, CA). The 
expression levels of RASSF2 mRNA were normalized to 18S, using a Ct threshold of 
0.1, in order to calculate ΔCt values for analysis using the comparative ΔCt method. 
Analysis was performed between the Dukes’ C (HT-29) CRC cell line as compared to the 
normal colon epithelium (CCD 841) cell line. 
i.  microRNA Transfection 
 Transfection experiments were conducted in two cell lines; CCD 841 (normal 
colon epithelium) and HT-29 (Dukes’ C CRC). Each cell line was transfected with each 
individual member of the miR-200 family, all five members of the family combined, and 
 80 
 
scrambled oligonucleotides as a negative control, using mirVana™ miRNA mimics (for 
CCD 841) and antagomirs (for HT-29) (Life Technologies, Carlsbad, CA).  
For our experiments, the concentration of the cell suspension was determined and 
cells plated into individual wells depending on the type of experiment being performed 
(Table 10). Once plated, cells were allowed a 24-hour acclimation period to adhere to the 
plate prior to transfection. After 24 hours when cells were 60-80% confluent in each well 
they were transfected using Lipofectamine® RNAiMAX  transfection reagent (Life 
Technologies, Carlsbad, CA) according to the manufacturer’s protocol. Firstly, miRNA 
(10μM) was diluted in Opti-MEM® Medium, followed by dilution of Lipofectamine® 
RNAiMAX Reagent in Opti-MEM® Medium. The diluted miRNA and Lipofectamine® 
were then combined in a 1:1 ratio and incubated at room temperature for five minutes. 
The miRNA-lipid complex was then added to each well. Incubation of the cells at 37˚C 
was performed for 24 hours after transfection prior to cell harvesting and further analysis. 





Table 10. Transfection Protocol Procedure Details. 
Experiment Plate Format Cell Concentration 
Final Transfection 













6-well 250,000/2mL 25 7.5 250 
RASSF2 and K-Ras 
Protein Quantification 
6-well 250,000/2mL 25 7.5 250 









j. Protein Quantification 
 Cell samples were removed from storage and thawed over ice. Two 1.5mL freeze 
tubes per sample were labelled with the cell line, date and miRNA clearly visible. The 
freeze tubes underwent sonication with two pulses per sample and were returned to ice. 
The sonicator was wiped with kimwipes between each sample and the process was 
repeated. Once complete, the samples were transferred into a 1.5mL tube and then 
centrifuged at 10,000rpm for ten minutes in order to pellet the debris. The upper layer of 
pure protein was transferred into a new 1.5mL labelled tube. 
1. Preparation of the protein standards 
Protein concentration was determined using the bicinchoninic acid (BCA) assay 
and performed in a 96-well plate. Protein standards were prepared in a serial 2-fold 
dilution down the plate. To begin, 20μL of double distilled water was pipetted into the 
wells of rows B-H in the first two columns on the plate. In the first two columns of row 
A, 40μL of BCA standard was added. Transferal of 20μL of BCA standard from well A 
to B was performed and mixed well. A further 20μL from mixed well B was transferred 
to well C. This process was repeated until row G. The remaining row H contained only 
20μL of double distilled water. The resulting total volume in each well was 20μL. 
2. Preparation of the protein samples (1:20 dilution) 
 Depending on the number of samples to be quantitated, 38μL of double distilled 
water was added to wells in the odd numbered columns from the third column onwards. 
Two microliters of protein sample was then added to each corresponding well and mixed 
thoroughly to make a total volume of 40μL. From each mixed water/protein sample, 
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20μL was transferred to the adjacent well. To read the amount of protein in each sample, 
equal amounts of Pierce™ BCA Protein Assay Reagent A and B (Thermo Scientific, 
Rockford, IL) were combined before 160μL was added to every well used, covered and 
incubated at 37˚C for 30 minutes. The 96-well plate was then read using a 
SPECTRAmax® PLUS 384 microplate spectrophotometer at a wavelength of 540nm.  
k. Western Blot 
 Western blots (n=5 for each protein) were performed for target proteins in the 
MAPK pathway (Table 11). Cell samples were prepared to contain a standardized 
amount of 40μg/μL of protein. Bolt® (4X) lithium dodecyl sulfate sample buffer was 
added to each sample, vortexed and heated for 10 minutes at 90˚C. A 10-well Bolt™ 8% 
Bis-Tris Plus Gel was placed in a Bolt® Mini Gel Tank which was then filled half-way 
with NuPAGE® MOPS SDS running buffer. Wells were loaded with 8μL molecular 
marker standards and 30μL protein sample. The remainder of the tank was then filled 
with running buffer. Gels were run at 165mV for 45 minutes in order to identify the 
proteins of interest. Once complete, the gel was transferred over 10 minutes onto a 
nitrocellulose membrane using the iBlot® Gel Transfer Device. The nitrocellulose 
membrane was then cut between the protein of interest and the endogenous internal 
reference, β-actin (MW 42kDa). The membrane was then blocked for β-actin in 5% milk 
or 5% Bovine Serum Albumin (BSA) in Tris-buffered saline and Tween 20 (TBS-T) for 
the protein of interest for 1 hour at room temperature on an orbital shaker. During the 
hour, primary antibodies for target proteins were made according to the manufacturer’s 
instructions. Primary antibodies were poured over the membranes and incubated 
 84 
 
Table 11. MAPK Pathway Proteins of Interest with Molecular Weight and Primary and 








RASSF2 37 1:1000 1:1000 








overnight at room temperature while being mixed. After three 5 minute washings with 
TBS-T, each membrane was submersed with horseradish-peroxidase-conjugated 
secondary antibody and mixed at room temperature for 1 hour. The membrane was again 
washed three times for 5 minutes each with TBS-T, incubated in equal parts of Enhanced 
Chemiluminescence (ECL) Reagents A and B for 5 minutes in the dark in order to detect 
the target protein, and then developed and imaged using a ChemiDoc MP imager 
(BioRad, Hercules, CA). 
l. Cell Proliferation 
 For cell proliferation studies, cells were grown in flasks until ready for use. Cells 
were split as previously described (pg.62) and cell concentration determined. HT-29 cells 
and CCD841 were plated in duplicate at a concentration of 100,000 cells/mL and 50,000 
cells/mL in individual wells in 12-well plates, respectively. Cells were left for 24 hours to 
adhere to the plate before being serum starved. For this, the medium from each well was 
removed and replaced using medium with a 0.5% FBS concentration. After 2 hours, this 
was removed and replaced with the normal growth medium and cells were then 
transfected with the respective antagomirs and mimics as previously described (pg.79-
80). Transfection was stopped after 24 hours, cells were trypsinized and once the cells 
were confirmed no longer adherent to the bottom of the plate, the trypsinization process 
was stopped. A 10μL sample from each well was inserted into a dual chamber counting 
slide (Bio-Rad, Hercules, CA) and cell number was measured each day for 5 days using 




m. Enzyme-Linked Immunosorbent Assay (ELISA) 
 Total and phosphorylated ERK1/2 was measured using the InstantOne™ ELISA 
96 Well (Affymetrix, Santa Clara, CA). Cell sample lysates were prepared from grown 
cells that had been plated and transfected in 6-well plates as previously described (pg.79-
80). Sample preparation of adherent cultured cells was prepared by removing media from 
the cells, and 300μL of pre-prepared cell lysis mix (1X) was added to each well. The 
plate was shaken at room temperature for 5 minutes. Each well was scraped with a pipette 
tip and the samples were collected in labeled tubes and stored at -80˚C until further use. 
Protein concentration was determined using the BCA assay previously described to 
ensure protein concentration was in the range of at least 0.1-0.5mg/mL in order to be 
detected.  
 When ready for use, cell lysates were thawed over ice and the desired number of 
InstantOne™ microplate strips needed for the experiment, including the positive control 
lysate and negative control, were determined. Unused microplate well strips were 
returned to the storage pouch and sealed until next use. Fifty μL of the positive and 
negative controls, and cell sample lysates to be tested were added to each of the assay 
wells. In addition, 50μL of prepared antibody cocktail mix was added to each well; the 
plate sealed and then incubated for 1 hour at room temperature on a microplate shaker at 
300rpm. Following incubation, the wells were washed three times with 200μL wash 
buffer (1X) /well and on completion any remaining wash solution was removed by 
inverting the plate on a paper towel. To this, 100μL of a detection reagent was added to 
each well and incubated for 30 minutes at room temperature with shaking at 300rpm. 
After 30 minutes, the reaction was stopped by adding 100μL stop solution to each well. 
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The plate was read by measuring the absorbance of the samples using the 
SPECTRAmax® PLUS 384 microplate spectrophotometer at a wavelength of 450nm.  
n. Statistical methods and analytic techniques 
1. Where possible, for each cell line and transfected miRNA, samples were prepared 
in replicates of five, unless stated. Cell culture samples were grown from new freezes and 
transfected at the same passage to maintain a true sample size of five. All reactions were 
run in duplicate and the averages of the duplicates used for analysis. Once obtained, all 
data was analyzed and graphs were prepared in GraphPad Prism v6.01 (GraphPad 
Software, Inc. La Jolla, CA). Data was tested for normality, and where confirmed, 
comparison of two data sets was conducted using an unpaired two-tailed Student’s t test. 
Statistical significance was defined as p<0.05 and data presented as mean ± standard 
deviation. 
 A t test was chosen as the most appropriate method for statistical analysis as we 
were performing comparisons between two groups for each experiment. If three or more 
groups (i.e. multiple cell lines) were being compared, analysis using ANOVA would 
have been performed. Sample size was justified at n=5, based on the preliminary cell line 
screening and validation of single miRNA expression. At a power of 80%, and adjusted 
α=0.05, if we were to detect a difference in mean miRNA expression between Dukes’ C 
CRC and normal colon epithelial cells of 1000 fold, a sample size of n=2 would be 
sufficient to detect a significant difference in miRNA expression between cell lines. We 
chose to perform experiments with n=5, to permit detection of smaller differences in 
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mean miRNA expression and other variables such as amount of protein, mRNA, and 
proliferation, and to keep all experimental replicates consistent. 
2. qRT-PCR 
 Raw fluorescence data (Ct values) generated by the Step-One Plus qRT-PCR 
instrument (Life Technologies, Carlsbad, CA) were exported for analysis using the 
comparative ΔΔCt method. The data was visualized on an amplification curve, and the 
threshold bar was set at 0.1. The value for the threshold bar was determined as it was 
consistently above the background noise, was within the exponential phase and was 
below the plateau and linear phases of the amplification curve. Where the threshold bar 
cut the amplification curve a Ct value was derived from the x-axis. All undetermined 
values were replaced with a Ct value of 40. The Ct value of each miRNA and mRNA was 
normalized to an endogenous control (RNU6 for miRNA and 18S for mRNA) generating 
a ΔCt. The ΔΔCt was calculated by the following; 
 ΔCt = Ct(target case)  - Ct(reference case) 
 ΔCt = Ct(target control)  - Ct(reference control) 
 ΔΔCt = ΔCt(case) - ΔCt(control) 
The resulting normalized gene expression level was calculated by 2(-ΔΔCt), representing 
the fold change between samples.  
3. Western Blot 
 The chemiluminescent blots were imaged first with the ChemiDoc MP imager 
(BioRad, Hercules, CA). The Band Analysis tools of ImageLab software version 5.2.1 
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(BioRad, Hercules, CA) were used to select and determine the background-subtracted 
density of the bands. Normalization was performed by dividing the relative density units 
of the protein of interest by the relative density units of the endogenous control, β-actin. 
The ratios obtained from this were analyzed as described above by averaging the ratios of 
each replicate for each sample and comparing the sample of interest against the negative 
control. 
4. ELISA Assay 
 Each sample replicate was run in duplicate and analyzed using the 
spectrophotometer at 450nm. Results were adjusted against the negative control (blank) 
and the absorbance units for each sample were averaged. A ratio of phosphorylated to 
total ERK 1/2 was calculated for each sample and a comparison of the ratios between 
each transfected miRNA sample and its corresponding negative control was performed.   
5. Cell Proliferation 
 Total cell numbers for each sample were obtained and averages of the duplicates 
were taken. For each of the five days, a comparison between total cell numbers of each 
transfected miRNA sample compared to the negative control was performed. Statistical 









We have previously identified increased expression of all members of the miR-
200 family in colorectal cancer compared to normal colon epithelium cell lines (pg. 36). 
The members of the miR-200 family are highly enriched in epithelial tissues and they 
have been linked to several cancers including CRC.(146) Using the results of our 
screening data, pathway analysis software identified all members of the miR-200 family 
to have a validated regulatory role upstream of Ras proteins in MAPK canonical pathway 
(pg. 45). Further analysis of the miR-200 family confirmed validated target interaction 
with Ras associated domain-containing protein 2 (RASSF2) (pg. 47). RASSF2 is one of 
six proteins in the RASSF family that in humans is encoded by the RASSF2 gene. 
RASSF2 is a negative regulator of Ras and binds directly to K-Ras within the Ras 
effector domain in a GTP-dependent process.(138) RASSF2 has previously been shown 
to promote apoptosis, cause cell cycle arrest and is regarded as a novel K-Ras-specific 
effector and potential tumor suppressor. Therefore, we hypothesize that RASSF2 
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expression will differ between CRC cell lines and a normal colon epithelial (CCD 841) 
cell line. 
b) Results 
1. RASSF2 mRNA Expression in Colorectal Cell Lines 
 RASSF2 mRNA expression was present in normal colon epithelial cell line 
samples across all replicates. Conversely, RASSF2 mRNA expression was lower or 
absent in each Dukes’ Stage CRC cell line. Dukes’ A (SW1116) and C (HT-29) CRC cell 
lines had no expression of RASSF2 mRNA, as determined by Ct values ≥40, whereas 
Dukes’ B (SW480) CRC had lower expression and Dukes’ D (T84) CRC cell lines had 
partial expression of RASSF2 mRNA, respectively. A representative qRT-PCR 
amplification plot of RASSF2 mRNA expression for all colorectal cell lines is shown in 
figure 24. Average Ct values (± standard deviation) representing relative expression of 
RASSF2 mRNA along with the internal control, 18S, are shown in table 12.  
 Comparison of expression of RASSF2 mRNA between each Dukes’ Stage CRC 
and the normal colon epithelial cell line showed significant downregulation in all Dukes’ 
Stage CRC cell lines. RASSF2 mRNA was downregulated with a fold regulation between 
-80 and -6828. Of all the CRC cell lines, Dukes’ C (HT-29) stage CRC had the largest 
downregulation of RASSF2 mRNA -6828 compared to the normal colon epithelial (CCD 





2. RASSF2 Protein Expression in Colorectal Cell Lines 
 The genes in DNA encode protein molecules which are required to carry out all 
functions necessary for life. Expressing a gene means manufacturing its corresponding 
protein. Initially, DNA is transferred to mRNA by a process called transcription. The 
resulting mRNA is a single-stranded copy of the gene, which then undergoes translation 
into a protein molecule. We have ascertained downregulation of RASSF2 mRNA in 
colorectal cancer cell lines compared to normal colon epithelium, the next step in the 
process to see whether this downregulation translated to the expression of RASSF2 
protein. 
 We observed the presence of RASSF2 protein in all normal colon epithelium 
(CCD 841) cell line samples, with a RASSF2/β-actin ratio of 0.014. No RASSF2 protein 
was detected in Dukes’ A (SW1116), C (HT-29) or D (T84) CRC samples, whereas 
Dukes’ B (SW480) CRC had a RASSF2/β-actin ratio of 0.016. Western blot results for 
all cell lines are shown in figure 26. There was a significant downregulation of RASSF2 
protein in Dukes’ A (SW1116), C (HT-29) and D (T84) CRC cell lines compared to the 
normal colon epithelial (CCD 841) cell line (p<0.05), whereas there was no difference in 
RASSF2 protein expression observed between the Dukes’ B (SW480) CRC cell line and 
















RASSF2 mRNA expression in Colorectal Cell Lines. Downregulation of RASSF2 mRNA was observed in all CRC cell lines compared 




Table 12. Average Cycle Threshold and ΔΔCt Values, and Fold Regulation for Expression of RASSF2 mRNA in All Colorectal Cell 
Lines 
Colorectal Cell Line 
Average Ct Values (+/- sd) 
Average ΔΔCt Values (+/- sd) Fold Regulation 
RASSF2 18S 
Dukes’ A CRC 
SW1116 
40.0 (+/- 0.0) 12.0 (+/- 0.1) 12.0 (+/- 0.1) -4174 
Dukes’ B CRC 
SW480 
33.9 (+/- 0.4) 11.6 (+/- 0.3) 6.3 (+/- 0.6) -80 
Dukes’ C CRC 
HT-29 
40.0 (+/- 0.0) 11.3 (+/- 0.1) 12.7 (+/- 0.1) -6828 
Dukes’ D CRC 
T84 
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Figure 25. RASSF2 mRNA Expression in Colorectal Cancer Cell Lines Compared to a 







 We found that there is a decreased expression of RASSF2 mRNA and protein in 
Dukes’ A (SW1116), C (HT-29) and D (T84) colorectal cancer cell lines compared to the 
normal colon epithelial (CCD 841) cell line, in keeping with previously reported studies.  
 Multiple studies have identified RASSF2 to have properties and behavior of a 
tumor suppressor gene. RASSF2 is a negative effector of Ras protein and it is inactivated 
by promoter hypermethylation in many cancers. Frequent downregulation of RASSF2 
has been detected in colorectal, gastric, lung, ovarian, cervical, and thyroid cancers; to 
name a few. Our results suggest that RASSF2 is implicated in colorectal carcinogenesis 
due to the significant difference observed in expression between normal colon epithelial 
and colorectal cancer cell lines.  
 Previous studies have identified association with methylation status of RASSF2 
and colorectal cancers and adenomas. RASSF2 methylation has frequently been observed 
in colorectal cancers and adenomas. One study reported RASSF2 methylation to be 
present in approximately 40% of all CRC and colorectal adenoma samples tested.(142) In 
addition to this, methylation of RASSF2 was significantly associated with KRAS and or 
BRAF mutations. Another more recent study showed that RASSF2 methylation was 
positively correlated with KRAS mutation in MSS, but not MSI, CRC.(140) Interestingly 
another study observed methylation of RASSF2 to be negatively associated with KRAS 
mutation in sporadic CRC. In this study, 75% of CRC specimens with RASSF2 





Figure 26. Western Blot Showing Expression of RASSF2 Protein in Normal Colon Epithelium (CCD 841) and Dukes’ Colorectal 








Presence of RASSF2 protein in normal colon epithelium and Dukes’ B colorectal cancer cell lines. Significant downregulation of 








almost 90% of all colorectal adenoma samples, suggesting that RASSF2 methylation is 
an early event in CRC. Another series observed concomitant KRAS and BRAF mutations 
in 73% of colorectal adenoma samples suggesting that the epigenetic changes occur 
simultaneously and may work synergistically.(147)  
 The CRC cell lines used in this study have differing KRAS and BRAF mutation 
status. We specifically chose to investigate MSS sporadic CRC cell lines. Of the four cell 
lines, only Dukes’ C (HT-29) CRC was KRAS wild type with BRAF mutation. The 
remaining three all had mutations of KRAS. It is possible that RASSF2 expression was 
present in the Dukes’ B (SW480) CRC cell line due to fact that not all CRC will have 
methylation of RASSF2 as previously described. If RASSF2 is not methylated, then 
inactivation will not occur and it is likely that CRC develops due to other genetic 
abnormalities and aberrant signaling events.  
Observing absent or downregulation of RASSF2 in colorectal cancer cell lines 
compared to a normal colon epithelial (CCD 841) cell line provides us with a platform in 
which to investigate the development of CRC. RASSF2 behaves as a Ras effector and 
functions as a tumor suppressor, therefore; if we are able to alter the expression of 








GAIN OF FUNCTION OF miR-200 FAMILY IN A NORMAL COLON EPITHELIAL 
(CCD 841) CELL LINE 
 
a) Introduction 
 We have seen that miR-200 family levels are decreased and RASSF2 mRNA and 
protein levels are present in a normal colon epithelial (CCD 841) cell line compared to 
the Dukes’ C (HT-29) CRC cell line. The purpose of the next series of experiments was 
to confirm the proposed oncogenic action of the miR-200 family members and the 
inhibitory effect they have on RASSF2 mRNA and subsequent RASSF2 protein 
expression. 
 Gain of function experiments with miRNA mimics are used to augment the 
function of endogenous miRNA for easier detection of a phenotypic change. In the case 
of the normal colon epithelium (CCD 841) cell line, endogenous levels of miR-200 
family members were low. Transfecting with miRNA mimics to supplement miR-200 
family function would therefore decrease the expression of the target gene RASSF2, and 
subsequent presentation of the phenotype.  
 From our previous knowledge, miRNA-200 family members all target RASSF2. 
RASSF2 is a negative regulator of K-Ras. Therefore; we hypothesized that increased 
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expression of miR-200 family members, would cause RASSF2 mRNA and protein levels 
to decrease in normal colon epithelial cells 
b) Results 
1. Overexpression of miR-200 family members in the normal colon epithelial (CCD 
841) cell line 
Transfection of miR-200a, miR-200b, miR-200c, miR-141, and miR-429 mimics 
into normal colon epithelial cells was successful (Figure 27). Increased expression of 
each individual miR-200 family member was achieved when compared to the negative 
control transfection (M-).  For all members of the miR-200 family, miRNA mimics 
achieved from 1084 to 5638 fold increase in the respective miRNAs (p<0.001) (Figure 
28).  
We also performed an experiment evaluating the additive effect of combining all 
five miR-200 family members into the same transfected wells, in an attempt to replicate 
what occurs in the natural environment. Transfection of the five miRNA mimics in 
combination increased expression of every miR-200 family member, as measured by 
qRT-PCR, compared to the negative control (Figure 29). 
2. Effect of Overexpression of miR-200 Family Members on RASSF2 mRNA 
 Manipulation of miR-200 expression led to changes in RASSF2 mRNA 
expression (Figure 30). miR-200a, miR-200b, miR-200c, and the combination of all five 
miR-200 family members were associated with decreased RASSF2 mRNA expression. 
miR-200b significantly downregulated RASSF2 mRNA with a fold regulation of -1.74  
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(p 0.016). There was no change in RASSF2 mRNA expression in the normal colon 
epithelial (CCD 841) cell line transfected with miR-141 and miR-429 (p 0.5 and 0.6, 
respectively) (Figure 31). 
3. Effect of Overexpression of miR-200 Family Members on RASSF2 Protein 
 Following transfection with miR-200 family member mimics, we observed a 
decrease in the relative expression of RASSF2 protein in the normal colon epithelial 
(CCD 841) cell line. RASSF2 protein levels were significantly lower in cells when 
transfected with miR-200a, miR-200b, miR-429, and the combination of all five miR-200 
















Amplification plot showing increased expression (denoted by the lower cycle number) of all miR-200 family mimics in the normal 
colon epithelial (CCD 841) cell line compared to the negative control.   
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Figure 28. miR-200 Family Expression in a Normal Colon Epithelial (CCD 841) Cell 















Transfection with individual miR-200 family miRNA mimics led to significant over 
expression of each individual miR-200 family member 24 hours after transfection of a 
normal colon epithelial (CCD 841) cell line. Data shown are mean ± standard deviation. 
* indicates p<0.001 vs. negative control.  
Transfected miRNA 
Fold Change  
(± sd) 
p-value 
miR-200a 2769 (±274) <0.001 
miR-200b 5638 (±485) <0.001 
miR-200c 1084 (±289) <0.001 
miR-141 4252 (±341) <0.001 
miR-429 2230 (±528) <0.001 
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*p < 0 .001
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Figure 29. miR-200 Family Expression in a Normal Colon Epithelium (CCD 841) Cell 














Transfection with the combination of all miR-200 family miRNA mimics led to a 
significant increase in expression of miR-200a, miR-200b, miR-200c, and miR-429 after 
24 hours. Data shown are mean * indicates p<0. 001 vs. negative control (M-).  
Transfected miRNA Fold Change p-value 
miR-200a 9353 <0.001 
miR-200b 16093 <0.001 
miR-200c 8013 <0.001 
miR-141 6626 <0.001 
miR-429 14551 <0.001 





















2 0 0 a 2 0 0 b 2 0 0 c 1 4 1 4 2 9
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0





















Significant downregulation of RASSF2 mRNA was observed in the normal colon epithelial (CCD 841) cell line transfected with miR-
200b after 24 hours. This can be observed by the later expression (higher cycle number) of RASSF2 compared to the negative control.  
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Figure 31. RASSF2 mRNA Expression in a Normal Colon Epithelial (CCD 841) Cell 
















Transfection with miR-200a, miR-200b, miR-200c, and the combination of all five miR-
200 family members led to decreased RASSF2 mRNA expression. Data shown are mean ± 
standard deviation. * indicates p<0.05 vs. negative control (M-).
Transfected miRNA Fold Regulation (± sd) p-value 
miR-200a -1.42 (±0.18) 0.077 
miR-200b -1.74 (±0.27) 0.016 
miR-200c -0.27 (±0.21) 0.760 
miR-141 1.15 (±0.26) 0.500 
miR-429 1.10 (±0.18) 0.610 
miR-200 Family (All) -0.66 (±0.13) 0.750 































*p < 0 .05
n=5





 miRNA mimics provide a means to study the function of specific miRNAs in a 
range of organisms, and to validate their role in regulating target genes. miRNA mimics 
are small, chemically modified double-stranded RNA molecules that are designed to 
mimic endogenous mature miRNAs, resulting in artificial down-regulation of target 
mRNA translation. Our results demonstrate the ability to successfully transfect and 
increase the expression of the miR-200 family. We have seen an increase in each 
individual miR-200 family member when transfected into normal colon epithelial cells, 
which in turn has led to a decreased expression of RASSF2 mRNA and protein levels 
compared to the negative control. Of importance to note, following transfection with 
miR-200 family mimics, the largest increase in fold change was observed with miR-200b. 
This corresponded with the largest downregulation of RASSF2 mRNA and subsequent 
protein expression, consistent with the idea that the higher the fold change observed, the 
more likely a response in down-regulation of the target mRNA. 
We also were successful in transfection of all five miR-200 family members in 
combination. By adding each miR-200 family mimic to cultured wells and measuring 
each individual expression, we observed much higher upregulation of miRNA expression 
than when transfected alone. This also resulted in the largest down-regulation of RASSF2 
protein expression. 
 It is worth noting the use of miRNA mimics and interpreting results with caution. 
It has recently been reported that it remains unclear as to whether transient transfection of 
















Transfection of miR-200a, miR-200b, miR-429, and a combination of all five miR-200 family mimics led to a significant decrease in 
RASSF2protein level compared to the negative control.  
37 kDa 
RASSF2 
β-actin 42 kDa 
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Figure 33. RASSF2 Protein Expression in a Normal Colon Epithelial (CCD 841) Cell 
Line Following Transfection with miR-200 Family Mimics. The Results Show the Ratio 
of RASSF2 Protein Relative to β-Actin, Expressed as Relative Density Units (RDu), for 












Decreased expression of RASSF2 protein was observed in a normal colon epithelial 
(CCD 841) cell line following transfection with miR-200a, miR-200b, miR-429, and the 
combination of all miR-200 family members. Data shown are mean ± standard deviation. 
* indicates p<0. 05 vs. negative control (M-). 



























*p < 0 .05
n=5
M e a n   s .d
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mimics at high concentrations in HeLa cells caused non-specific alterations in gene 
expression, while at low concentrations achieved expression levels comparable to other 
methods, such as lentiviral infection or plasmid transfection, but failed to efficiently 
suppress target gene expression. (148) We performed transfection at 24 and 48 hours and 
at 48 hours saw inconsistency within miRNA expression of the negative control. This led 
us to believe that transfection after 48 hours was inadequate and the results could not be 
appropriately interpreted, hence a transfection time of 24 hours was implemented. To 
minimize the risk of over expressing miRNA levels beyond normal pathological levels, 
we followed the manufacturer’s recommendations. For each individual miR-200 family 
member a 25pmol transfection concentration was used, up to a maximum total of 
125pmol when combining all five miR-200 family members together. These 
concentrations were within the limits of transfection described by Jin et al.  
 In conclusion we have managed to demonstrate significant upregulation of the 
miR-200 family in normal colon epithelial cells in contrast to the relatively low or absent 
baseline expression. This has in turn led to a decrease in RASSF2 mRNA expression 
consistent with the hypothesis that miR-200 family members target RASSF2. By 
demonstrating reduced RASSF2 protein expression we are now able to examine the 
effects of increasing the expression of the miR-200 family and its role within activity of 




LOSS OF FUNCTION OF miR-200 FAMILY IN DUKES’ C (HT-29) COLORECTAL 
CANCER CELL LINE 
 
a) Introduction 
 Dukes’ C (HT-29) CRC cell line was chosen for investigation over other cell lines 
for three reasons, 
 it had consistently higher expression of each individual miR-200 family member 
on initial screening compared to the other three CRC cell lines. We believed that 
in order to reduce expression of miRNAs using miRNA antagomirs, a cell line 
with higher expression of the miRNAs to be investigated would provide the best 
opportunity to detect downregulation.  
 the HT-29 Dukes’ C CRC cell line is microsatellite stable, within the MAPK 
pathway it is KRAS is wild type and is not mutated like the other CRC cell lines 
we screened. 
 it is a metastatic cell line (derived from a cancer with lymph node metastasis) and 
therefore observations made on it would have direct clinical relevance and 
applicability with respect to designing newer treatment modalities.
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 miRNA antagomirs suppress the function of endogenous miRNAs. They prevent 
miRNAs from binding to its desired mRNA binding site, thus increasing its target gene 
expression. In previous experiments we have observed miR-200 family members to be 
highly expressed in the Dukes’ C (HT-29) CRC cell line. We have also seen that 
increasing the expression of miR-200 family members in a normal colon epithelial (CCD 
841) cell line reduces the expression of RASSF2 mRNA and RASSF2 protein. 
The purpose of these experiments is to determine whether the reverse process is 
true in a CRC cell line. We therefore; hypothesized that by decreasing expression levels 
of miR-200 family members we would expect to see increased expression of RASSF2 
mRNA and subsequent RASSF2 protein expression. 
b) Results 
1. Inhibition of miR-200 family members in the Dukes’ C (HT-29) CRC cell line 
 Transfection of miR-200 family antagomirs to reduce expression of each miRNA 
was confirmed by qRT-PCR. Downregulation was observed in three of these miRNAs, 
significantly for cells transfected with miR-200b and miR-200c antagomirs with a fold 
downregulation of -2.8 and -10.6, respectively (p<0.01) (Figure 34). When transfection of 
all five miR-200 family members in combination was performed, there was significant 
downregulation of miR-200a, miR-200b, miR-200c, and miR-429 (p<0.01) (Figure 35). 
2. Effect of Inhibition of miR-200 Family Members on RASSF2 mRNA 
 In our preliminary cell line screening, we did not identify RASSF2 mRNA 
expression in the Dukes’ C (HT-29) CRC cell line. By knocking down expression of the 
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miR-200 family, we observed an increase in RASSF2 mRNA expression in this Dukes’ C 
(HT-29) CRC cell line, significantly for miR-429 (p<0.001) Transfection of all five miR-
200 family members in combination, significantly up-regulated RASSF2 mRNA 
expression 3.7 fold (p<0.01) (Figure 36). 
3. Effect of Inhibition of miR-200 Family Members on RASSF2 Protein 
 In our preliminary cell line studies, we did not detect the presence of RASSF2 
protein in the Dukes’ C (HT-29) CRC cell line. Transfection with miR-200 family 
antagomirs demonstrated expression of RASSF2 protein in all samples, as detected by 
Western blot (Figure 37). Significant up-regulation of RASSF2 protein was observed in 
the Dukes’ C (HT-29) CRC cell line transfected with miR-141, miR-429, and all five 
miR-200 family members in combination, compared to the negative control (A-) (p< 
0.05) (Figure 38). 
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Figure 34. miR-200 Family Expression in a Dukes’ C (HT-29) Cell Line Following 














Transfection with miR-200 family miRNA antagomirs led to a significant decrease in 
expression of miR-200b and miR-200c after 24 hours. Data shown are mean ± standard 
deviation. * indicates p<0. 01 vs. negative control (A-).  
miRNA Antagomirs Fold Regulation (± sd) p-value 
miR-200a 1.2 (±0.2) 0.149 
miR-200b -2.8 (±1.1) <0.01 
miR-200c -10.6 (±2.1) <0.001 
miR-141 -1.1 (±0.4) 0.751 
miR-429 1.1 (±0.2) 0.594 


































*p < 0 .01
n=5
* * ** p < 0 .001
M e a n   s .d
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Figure 35. miR-200 Family Expression in a Dukes’ C (HT-29) CRC Cell Line Following 


















Transfection with the combination of all miR-200 family miRNA antagomirs led to a 
significant decrease in expression of miR-200a, miR-200b, miR-200c, and miR-429 after 
24 hours. Data shown are mean ± standard deviation. * indicates p<0. 01 vs. negative 
control (A-).  
miRNA Antagomirs Fold Regulation (± sd) p-value 
miR-200a -2.16 (±0.6) <0.01 
miR-200b -1.49 (±0.1) <0.01 
miR-200c -5.97 (±0.7) <0.001 
miR-141 -1.74 (±1.0) 0.07 
miR-429 -1.61 (±0.2) <0.001 





































** p < 0 .001
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Figure 36.  RASSF2 mRNA Expression in a Dukes’ C (HT-29) CRC Cell Line Following 









Transfected miRNA Fold Change (± sd) p-value 
miR-200a 3.64 (± 2.5) 0.12 
miR-200b 3.88 (± 2.7) 0.08 
miR-200c 3.25 (± 2.6) 0.15 
miR-141 4.00 (± 1.5) 0.12 
miR-429 3.82 (± 0.8) <0.001 
miR-200 Family (All) 3.71 (± 0.5) <0.01 
 
Transfection with miR-200 family antagomirs led to increasedRASSF2 mRNA expression. 
Data shown are mean ± standard deviation. * indicates p<0.01, ** p<0.001 vs. negative 
control (A-).




























*p < 0 .01
**
** p < 0 .001
n=5




 Following transfection of a Dukes’ C (HT-29) CRC cell line with miR-200 family 
antagomirs we observed down-regulation of individual miR-200 family members up to 
10 fold. miRNA inhibitors are chemically modified, single-stranded oligonucleotides 
designed to specifically bind to and inhibit endogenous miRNAs, resulting in artificial 
up-regulation of target mRNA translation. The binding of the antagomir with the target 
miRNA leads to the degradation of the miRNA by the same process as described for 
short interfering RNAs.(149)  
We demonstrated significant down-regulation of miR-200b and miR-200c in a 
Dukes’ C (HT-29) CRC cell line and upregulation of RASSF2 mRNA when transfecting 
cells with each individual miR-200 family antagomir. Although not a significant finding, 
we believed the more important observation of miR-200 family inhibition would manifest 
at the protein level.   
 In untransfected Dukes’ C (HT-29) CRC cell lines, there was absent expression of 
both RASSF2 mRNA and protein. The fact we were able to observe amplification of 
RASSF2 at any level was encouraging. Again, transfection of all five miR-200 family 
members in combination produced the most significant RASSF2 mRNA expression. 
It is possible that transient transfection could affect miRNA silencing and 
ultimately the results we observe. Anecdotally, inhibition of miRNA using miRNA 














Knockdown of miR-200 family members led to an increase in RASSF2protein level compared to the negative control (A-). 
  
37 kDa RASSF2 
β-actin 42 kDa 
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Figure 38. RASSF2 Protein Expression in a Dukes’ C (HT-29) CRC Cell Line Following 
Transfection with miR-200 Family Antagomirs. The Results Show the Ratio of RASSF2 
Protein Relative to β-Actin, Expressed as Relative Density Units (RDu), for each miRNA 











Increased expression of RASSF2 protein was observed in the Dukes’ C (HT-29) CRC cell 
line following transfection with miR-141, miR-429, and the combination of all miR-200 
family members. Data shown are mean ± standard deviation. * indicates p<0. 05 vs. 
negative control (A-).  































M e a n   s .d
 120 
 
amount to which expression of a target gene is reduced, such as, transfection efficiency, 
transcription rate of the gene of interest, mRNA and protein stability, and the growth 
characteristics of the particular cell line used.(150) In our experience, Dukes’ C (HT-29) 
CRC cells are very quick to divide and grow and this may be a factor in the limited 
success of miRNA antagomir transfection as accelerated growth may outweigh the 
supply. Lipofectamine RNAiMAX used in our experiments has been developed to 
increase the transfection efficiency of RNA into in vitro cell cultures. Lipofectamine 
reagent contains lipid subunits that can form liposomes in an aqueous environment, 
which entraps the transfection agent, in this case miRNA antagomirs. It is a cationic 
liposome formulation which joins with negatively charged nucleic acid molecules 
allowing them to overcome the electrostatic repulsion of the cell membrane.(151, 152) 
Fusion with the negatively charged plasma membrane occurs allowing the nucleic acid to 
cross into the cytoplasm. The contents are available to the cell for replication or 
expression, however; the nucleic acid must reach the cell nucleus to begin transcription. 
Issues could arise, for example, if the material never reaches the nucleus in the first place, 
or if it becomes trapped in the reassembling nuclear envelope following mitosis.(150)  
Another consideration would be to perform multiple transfections. This would 
enable newly grown cells to take up the lipid complex and miRNA antagomir. However, 
transfection-mediated cytotoxicity can be an issue and can mask the true phenotype of the 
target gene being studied and also affect cell viability. Increasing the frequency of 
transfection was not considered to be a viable option in our experiments, as we have 
already demonstrated that a greater than 24 hour transfection was detrimental to cell 
function and that interpretation of the results at 48 hours was unreliable. 
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In conclusion, we have demonstrated the ability to down-regulate expression of 
members of the miR-200 family which were highly expressed in Dukes’ C (HT-29) CRC 
cells. In doing so, we have upregulated expression of RASSF2 mRNA and protein. This 
suggests that inhibition of miR-200 family members increases RASSF2 expression. This 
warrants further investigation on the effect of inhibition of the miR-200 family and 









 In our previous experiments we demonstrated that successful overexpression of 
the miR-200 family in a normal colon epithelial (CCD 841) cell line leads to reduced 
expression of RASSF2 mRNA and RASSF2 protein. Conversely, knockdown of the miR-
200 family members in a Dukes’ C (HT-29) CRC cell line leads to an increased 
expression of RASSF2 mRNA and RASSF2 protein. RASSF2 is a known negative 
regulator of Ras and binds directly to K-Ras, within the MAPK pathway, in a GTP-
dependent manner. Once K-Ras is activated, it initiates a phosphorylation cascade of 
downstream proteins resulting in altered gene expression. miRNAs from the miR-200 
family have been shown to promote cell proliferation when transfected into various cell 
lines and may impact K-Ras expression and downstream pathways.(153) As the miR-200 
family target RASSF2, and considering that RASSF2 is a negative regulator of K-Ras, 
manipulation of miR-200 family expression may lead to changes within the MAPK 
pathway affecting transcription factors and the resulting downstream functional processes 
such as cell proliferation (Figure 39).
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RASSF2 is a negative regulator of Ras. It binds directly to K-Ras in a GTP-dependent 
manner via the Ras effector domain. The miR-200 family target RASSF2 and changes in 
expression could affect transcription factors and the resulting downstream functional 





 We propose that by manipulating the expression of the miR-200 family members 
in a normal colon epithelial (CCD 841) and a Dukes’ C (HT-29) CRC cell line we will 
affect total K-Ras expression thereby leading to a change in activity within the MAPK 
pathway, as measured by the phosphorylation of ERK 1/2, a downstream protein within 
this pathway. We also hypothesize that increased activation of ERK 1/2 in a normal colon 
epithelial (CCD 841) cell line will result in increased cell proliferation, suggesting 
oncogenic-like properties, whereas decreased ERK 1/2 activation in a Dukes’ C (HT-29) 
CRC cell line will result in decreased cell proliferation, highlighting the potential use of 
miR-200 family as a therapeutic target in CRC. 
b) Results 
 Total K-Ras Expression 
 Following successful transfection of a normal colon epithelial (CCD 841) cell line 
with miR-200 family members we observed an increase in total K-Ras expression in cells 
transfected with miR-200a, miR-141 and miR-429 compared to the negative control (M-) 
(p< 0.05) (Figures 40 & 41). 
 In a Dukes’ C (HT-29) CRC cell line total K-Ras was increased compared to the 
negative control (A-) following transfection with miR-200a and miR-200c (p< 0.05) 






ERK 1/2 Activation 
 In a normal colon epithelial (CCD 841) cell line, measurement of total and 
phosphorylated ERK 1/2 was performed following transfection with miR-200 family 
mimics. We observed an increased ratio of phosphorylated to total ERK 1/2 compared to 
the negative control (M-). This indicates a significant activation of the MAPK pathway 
for all miR-200 family mimics (p < 0.01) (Figures 44 & 45). 
 In the Dukes’ C (HT-29) CRC cell line, measurement of total and phosphorylated 
ERK 1/2 following transfection with miR-200 family antagomirs, showed a decreased 
ratio of phosphorylated to total ERK 1/2 compared to the negative control (A-) indicating 
a significant decrease in MAPK pathway activation for cells transfected with miR-200a, 
miR-200b, miR-141, and the combination of all five miR-200 family member antagomirs 






Figure 40.Western Blots for Total K-Ras Protein Expression in a Normal Colon 
Epithelial (CCD 841) Cell Line. 
 
Representative Western blot images showing total K-Ras expression. Bands were 





























*p < 0 .05
n=4
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Figure 41. Total K-Ras Protein Expression in a Normal Colon Epithelial (CCD 841) Cell 














An increase in total K-Ras expression was observed in cells transfected with miR-200a, 
miR-141 and miR-429 compared to the negative control (M-). Data shown are mean ± 
standard deviation. * indicates p<0. 05 vs. negative control (M-).  
miRNA 
mimics 
Average Ratio  
(K-Ras/β-actin) 
p-value 
miR-200a 0.618 0.026 
miR-200b 0.580 0.178 
miR-200c 0.439 0.769 
miR-141 0.674 0.009 





Figure 42. Western Blots for Total K-Ras Protein Expression in a Dukes’ C (HT-29) 
CRC Cell Line. 
 
Representative Western blot images showing total K-Ras expression. Bands were 
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Figure 43. Total K-Ras Protein Expression in a Dukes’ C (HT-29) CRC Cell Line 














An increase in total K-Ras expression was observed in cells transfected with miR-200a, 
and miR-200c compared to the negative control (A-). Data shown are mean ± standard 
deviation. * indicates p<0. 05 vs. negative control (A-).  
miRNA  
antagomirs 
Average Ratio  
(K-Ras/β-actin) 
p-value 
miR-200a 0.051 0.027 
miR-200b 0.039 0.286 
miR-200c 0.043 0.040 
miR-141 0.059 0.089 
miR-429 0.048 0.166 
A- 0.030  
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 Cell Proliferation 
 Measuring cell proliferation as the resulting functional outcome of activity within 
the MAPK pathway was performed for both normal colon epithelial (CCD 841) and 
Dukes’ C (HT-29) CRC cell lines. Following transfection of miR-200 family mimics in 
the normal colon epithelial (CCD 841) cell line, we observed a significant increase in cell 
proliferation at day five in cells transfected with miR-200a, miR-200c and miR-141 
mimics compared to the negative control (p < 0.05) (Figure 48). Cell proliferation was 
also increased in the normal colon epithelial (CCD 841) cell line following transfection 
with miR-200a at days 2, 4 and 5 (p < 0.01). 
No significant increase in cell proliferation was observed for miR-200b, miR-429, 
and when all five miR-200 family members were transfected into cells in combination. 
Cell proliferation growth curves for each miR-200 family member are shown in figure 
49. 
In the Dukes’ C (HT-29) CRC cell line, cell proliferation was significantly 
decreased following transfection for individual (p < 0.001) and the combination of all 
miR-200 family member antagomirs (p < 0.05) at day five compared to the negative 
control (Figure 50). miRNAs-200b, miR-200c, miR-141, miR-429, and the combination 
of all five miR-200 family members had a significant decrease in cell proliferation at day 
four (p < 0.05). Cell proliferation growth curves for each miR-200 family member are 




Figure 44. ELISA Measurement of Total and Phosphorylated ERK 1/2 in a Normal Colon 
Epithelial (CCD 841) Cell Line Following Transfection with miR-200 Family Mimics. 
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Figure 45. ERK 1/2 Activation in a Normal Colon Epithelial (CCD 841) Cell Line 










Increased ratio of phosphorylated to total ERK1/2 compared to negative control (M-) 
indicates significantly increased activation of the MAPK pathway for all miR-200 family 
mimics. Data shown are mean ± standard deviation. * indicates p<0. 01 vs. negative 





200a 0.249 0.002 
200b 0.191 <0.001 
200c 0.146 <0.001 
141 0.139 <0.001 
429 0.128 <0.001 
miR-200 Family (All) 0.122 <0.001 
M- 0.060  
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Figure 46. ELISA Measurement of Total and Phosphorylated ERK 1/2 in a Dukes’ C 
(HT-29) CRC Cell Line Following Transfection with miR-200 Family Antagomirs. 
 


































*p < 0 .05
n=5
*
M e a n   s .d
Figure 47. ERK 1/2 Activation in a Dukes’ C (HT-29) CRC Cell Line Following 













Decreased ratio of phosphorylated to total ERK1/2 compared to negative control (A-) 
indicates significantly decreased activation of the MAPK pathway for miR-200a, miR-
200b, and 141 and the combination of all five miR-200 family member antagomirs. Data 





200a 0.060 0.031 
200b 0.060 0.001 
200c 0.069 0.166 
141 0.048 0.017 
429 0.064 0.189 
miR-200 Family (All) 0.066 0.024 




 We have demonstrated that overexpression of miR-200 family members and a 
reduction in RASSF2 protein expression leads to increased K-Ras expression in normal 
colon epithelial (CCD 841) cells transfected with miR-200a, miR-200b, miR-141, and 
miR-429 mimics. In addition, greater expression of miR-200 family members also 
increases activation of the MAPK signaling pathway as demonstrated by enhanced 
phosphorylation of ERK 1/2 in relation to total levels (Figure 39). This increase in 
activity may also explain the observed increase in cell proliferation as a measure of a 
functional outcome of the increased MAPK pathway activity. 
 Conversely, loss of function of miR-200a and miR-200c in Dukes’ C (HT-29) 
CRC cells results in increased K-Ras expression, confirming previous findings that miR-
200c is inversely correlated with K-Ras expression in certain cancers. (154) Despite the 
increase in K-Ras expression, we observed a decreased ratio of phosphorylated to total 
ERK 1/2 associated with loss of function in miR-200a, miR-200b, and miR-141, 
indicating MAPK pathway inactivation. MAPK pathway inactivation may explain the 
significant decrease in cell proliferation seen for all members of the miR-200 family. 
  The ERK MAPK signaling pathway is regarded as one of the most important 
regulators of cell proliferation.(155) There is growing evidence to suggest that activation 
within this pathway is involved in the pathogenesis, progression, and oncogenic behavior 




Figure 48. Cell Proliferation in a Normal Colon Epithelial (CCD 841) Cell Line 







Cell count as a measurement of proliferation shows statistically significant increase in 

















Figure 50. Cell Proliferation in a Dukes’ C (HT-29) CRC Cell Line Following 








Cell count as a measurement of proliferation shows statistically significant decrease in 


















to tumorigenesis. Changes in ERK signaling may contribute to cell cycle arrest in the 
G2/M phase.(156) Ras activity is another observation suggestive of MAPK pathway 
activation. High Ras activity is accompanied by an increased ERK 1/2 activity.(157) We 
have demonstrated higher K-Ras expression following transfection with miR-200 family 
mimics and antagomirs. Whilst we might expect to see lower levels of K-Ras in Dukes’ C 
(HT-29) CRC cell lines transfected with miR-200 family antagomirs, hence reducing 
downstream ERK 1/2 activity, we saw an increase in total K-Ras levels compared to the 
negative control. Although miRNAs are typically associated with decreased protein 
expression, a possible explanation could be differential activation of K-Ras expression 
and repression of translation through separate base-pairing mechanisms. In addition, 
although we cannot make a direct comparison between the normal colon epithelial (CCD 
841) cell lines, transfected with miR-200 family mimics, compared to the Dukes’ C (HT-
29) CRC cell lines, transfected with miR-200 family antagomirs, it would be worth 
noting the total K-Ras expression ratios. The ratio of total K-Ras to β-actin in normal 
colon epithelial (CCD 841) cell lines was approximately ten times higher than the ratio of 
total K-Ras to β-actin in Dukes’ C (HT-29) CRC cell lines (~0.6 vs. 0.05). This might 
suggest to us that we did observe a reduction in overall levels of total K-Ras in Dukes’ C 
(HT-29) CRC cells hence the resulting decrease in ERK 1/2 activation seen.     
Association of the miR-200 family and interaction with the MAPK signaling 
pathway is well documented. The majority of knowledge regarding the miR-200 family is 
the involvement with epithelial to mesenchymal transition (EMT). The miR-200 family 
promotes the epithelial state by suppressing epithelial gene transcriptional repressors, 
Zeb1/Zeb2. In one study, overexpression of miR-200c was associated with enhanced 
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EGFR and MAPK signaling pathways and lead to suppression of cell invasion in mouse 
breast cancer cells.(158) There is also evidence to support the association of miR-200 and 
KRAS. In a mutant K-Ras lung adenocarcinoma mouse model, overexpression of miR-
200a, miR-200b, and miR-429 inhibited tumor growth and metastasis.(159) In addition to 
the miR-200 family association with tumor cell invasion, they have been identified to 
govern other tumor cell biologic processes, such as proliferation.(160) miR-200c has 
been shown to modulate KRAS in breast cancer cell lines. KRAS silencing by miR-200c 
lead to reduced proliferation in KRAS wild-type but not KRAS mutated breast cancer 
cell lines.(154)  
Dysregulation of the miR-200 family has been observed to be both up-regulated 
and down-regulated in different types of cancer. The majority of functional studies, 
particularly in breast cancer, concentrate on down-regulation of miR-200, suggesting that 
miR-200 members prevent tumor progression.(161) Despite this, identification of up-
regulation of the miR-200 family in cancers, including colorectal cancer, suggests that 
miR-200 family members may in fact be promoting progression of certain cancers. In 
melanoma cell lines, the levels of miR-200 family members were increased compared to 
normal melanocytes, and expression did not suppress tumor invasion.(160) They 
identified that up-regulation of miR-200a and miR-200c drives different modes of tumor 
cell invasion, either “mesenchymal-type” or “amoeboid-like”. Overall, this group 
questioned previous findings of the role of the miR-200 family in suppressing invasion 
and metastasis. To support these findings, two other recent studies identified that 
overexpression of the miR-200 family promoted cell proliferation in culture, and 
metastasis in vivo.(153, 162) 
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We believe our findings that a reduction in miR-200 family members leads to a 
decrease in MAPK pathway activity and a reduction in cell proliferation in Dukes’ C 
(HT-29) CRC cell lines is novel, and suggests that the miR-200 family acts as an 
oncogene in CRC. This provides an opportunity to develop new and targeted therapies to 




CONCLUDING REMARKS AND DIRECTION OF FUTURE STUDIES 
 
 The identification of high expression of the miR-200 family in CRC cell lines 
compared to a normal colon epithelial (CCD 841) cell line allowed us to investigate the 
role of this family in the progression of CRC. Previous research with the miR-200 family 
has focused on EMT of cancer cells where dysregulation is considered to exhibit tumor 
suppressive behavior. However; in various cancers increased levels of some individual 
members of the miR-200 family contradicts the tumor suppressive role of this miRNA 
family. The purpose of this project was to investigate the role of the miR-200 family in 
CRC cell lines in order to gain a better understanding regarding the role that this family 
plays in colorectal cancer.  
Here, we have identified an association between the miR-200 family and the 
RASSF2 tumor suppressor, and have investigated their impact on activity within the 
MAPK signaling pathway. Overexpression of the miR-200 family in a normal colon 
epithelial (CCD841) cell line reduces the expression of RASSF2 protein. RASSF2 binds 
to K-Ras. Loss of RASSF2 protein expression increases K-Ras and subsequent activity 
with the MAPK signaling pathway, as measured by the downstream pathway protein 
ERK 1/2. The resulting outcome is increased cell proliferation, a marker of oncogenesis.
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Conversely, when expression of the miR-200 family in a Dukes’ C (HT-29) CRC cell 
line is reduced, RASSF2 protein expression increases and subsequent MAPK signaling 
pathway activity decreases. Measurement of cell proliferation confirmed the reduced 
growth of these cells. A summary of our results are outlined on page 147. 
 We have demonstrated the ability of the miR-200 family to transform normal 
epithelial cells into cells with more cancer-like behavior, and to transform CRC cells to 
cells with a more normal, less malignant behavior. These findings suggest the potential of 
the miR-200 family to be developed as a therapeutic target in CRC. Current standard 
therapies used in the treatment of CRC include the chemotherapy regime of FOLFOX 
(oxaliplatin, 5-FU and leucovorin). This is based on the MOSAIC trial which showed that 
in patients with Stage II or III colon cancer, those treated with FOLFOX therapy versus 
5-FU and leucovorin had a significantly higher 3-year disease free survival.(163) More 
recently, newer agents have been developed to specifically target the gene and protein 
changes in cells that cause cancer. Epidermal growth factor receptor (EGFR) protein is 
often highly expressed on the surface of cancer cells and is recognized as an important 
player in CRC initiation and progression. Anti-EGFR drugs have been developed to 
target this protein and reduce cell growth, however; in patients who have a KRAS 
mutated CRC, the treatment is ineffective.(164) Similarly, MEK inhibitors have been 
developed to target MAPKK enzymes, MEK 1/2, in the MAPK pathway which is often 
overactive in some cancers. MEK inhibitors are effective in the treatment of 
KRAS/BRAF mutated, but not wild-type CRC.(165)  
 There are several limitations to this work. Firstly, the use of colorectal cell lines in 
research is a cost effective, easy to use method, and provides a pure population of cells 
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that are consistent and reproducible, to name but a few advantages. The popularity for the 
use of cell lines in research is growing, based upon the number of cell lines available for 
use and numerous publications. However; care must be taken when interpreting the 
results as serial passage of cell lines can cause phenotypic changes within these cells and 
these cells may not always accurately replicate characteristics of the primary cells. 
Another problem to note is that of contamination with other cell lines and infection with 
mycoplasma. Secondly, transient transfection is most commonly used to investigate the 
short-term impact of alterations in gene and protein expression. During transient 
transfection, the nucleic acid sequence is not integrated into the cell genome and the 
effect on the target gene expression is temporary. Our transfection time was limited to 24 
hours to allow for this. Lastly, we investigated the change in miR-200 family expression 
in a KRAS wild-type sporadic CRC cell line. KRAS mutations are present in up to 50% 
of cases of CRC and occur as point mutations at codons 12 and 13. RASSF2 binds to K-
Ras in the effector binding area on the protein, separate from the area where the 
mutations occur, therefore, for the purposes of this study, the KRAS mutation status 
should not affect our results. However; for completeness it would be worthwhile to 
investigate the role of the miR-200 family in a KRAS mutated CRC cell line for 
comparison.  
Based on sample size calculations from the screening and validation of 
dysregulated miRNAs in colorectal cancer cell lines compared to the normal colon 
epithelial cell line (CCD841) a sample size of n=2 was required to achieve a power of 
80%.  As previously described we chose to perform all experiments with five 
experimental replicates to allow for the detection of smaller differences in other 
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variables. When measuring RASSF2 mRNA levels, we observed a trend in upregulation 
or downregulation, depending on the cell line and miRNA transfection in our replicates, 
but this did not reach statistical significance for all the individual miR-200 family 
members. It is possible that by increasing the sample size, e.g. n=10, for experiments 
where differences in expression were found to be more subtle, we would narrow the 
standard deviation and variability, and observe significant differences in cells transfected 
with either miR-200 family mimics or antagomirs.  
Future considerations include clinical correlation with CRC patient tissue 
samples. For example, the use of a tissue microarray to permit simultaneous analysis of 
miR-200 family expression and RASSF2 mRNA and protein levels and correlate the 
findings with clinical factors would be of interest. In addition, the effects of the miR-200 
family on CRC could be measured by using a mouse model. An established miR-
200c/miR-141 knockout mouse would allow for investigation into the oncogenic features 
of the miR-200 family and also allow for testing of miR-200 therapies, such as miRNA 
inhibition therapy using  miRNA antagonists e.g. siRNA, as a potential treatment in 
CRC. 
From our colorectal cell line screening we found significant dysregulation of 
many miRNAs. While we chose to study the upregulated miR-200 family it is important 
to consider the significantly downregulated miRNAs. Comparison of the downregulated 
miRNAs in our colorectal cancer cell lines revealed five miRNAs to be common to all, 
miR-199a, miR-409, miR-485, miR-541 and miR-654. Each of these miRNAs has been 
shown to be involved in cancer pathogenesis.(166-170) Of interest, miR-409 expression 
was significantly downregulated in colorectal cancer tissues and negatively regulated 
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CRC metastatic capacities, including suppressing cancer cell migration, invasion and 
metastasis.(167) miR-199a and miR-541 have previously been regarded as tumor 
suppressors and miR-199a has been identified to regulate the tumor suppressor MAP3K. 
An area of interest for future study would involve investigation of these downregulated 
miRNAs and their associated pathways. It would be interesting to evaluate any targets 
common to both the miR-200 family and the downregulated miRNAs with the aim to 
enhance miRNA therapy in colorectal cancer in addition to the newer targeted drug 
therapies. 
 The miR-200 family has previously been studied in regards to its regulation of 
EMT. EMT is the process where an epithelial cell loses apical/basolateral polarity, severs 
intercellular adhesive junctions, degrades basement membrane components and becomes 
a migratory mesenchymal cell i.e. enables cells from the primary cancer to travel to 
regional nodes or metastatic sites. The miR-200 family plays an important role in 
regulating EMT inhibiting the initial step of metastasis by maintaining the epithelial 
phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and 
ZEB2. Members of the miR-200 family have therefore been believed to play an essential 
role in tumor suppression.(161) One of the main pathways involved in this process is the 
transforming growth factor beta (TGF-β) signaling pathway. TGF-β signaling pathway is 
involved in many cellular processes and suppresses tumor formation by inhibiting cell 
growth and promoting apoptosis. In advanced cancers it has been shown to promote 
tumor formation by its ability to induce EMT.(171) TGF-β also induces other signaling 
pathways and activates the ERK MAPK pathway by allowing the binding of the Grb2-
Sos1 complex which activates Ras. The interaction of the miR-200 family in both of 
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these signaling pathways is interesting as they play differing roles within each. This 
would certainly be an area of interest to study further and improve our understanding of 
the cellular processes regulating cancer development. 
A recently identified pathway regulated by the miR-200 family is the PI3K/AKT 
pathway. This pathway is important in regulating the cell cycle and is directly related to 
cell proliferation and apoptosis. Overactivation of this pathway is commonly observed in 
cancer. miR-200 activates the PI3K/AKT pathway by targeting FOG2 acting as a PI3K 
antagonist. miR-200 was observed to activate AKT through a novel mechanism involving 
inactivation of S6K, thus promoting tumor growth.(172) 
 In conclusion we have identified a novel finding regarding the role of the miR-
200 family on the tumor suppressor RASSF2 and subsequent activity within the MAPK 
signaling pathway in CRC.  We have demonstrated the transition of a normal colon 
epithelial (CCD 841) cell line towards a “cancer-like” colorectal cell by increasing the 
expression of members of the miR-200 family. Conversely, reduction of miR-200 family 
expression in a Dukes’ C (HT-29) CRC cell lines reverses this process and the CRC cells 
begin to show less “cancer-like” features. This improved understanding of the oncogenic 
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A-    miRNA Antagomir Negative Control 
AJCC    American Joint Committee on Cancer 
AKT    Protein Kinase B (PKB) 
APC    Adenomatous Polyposis Coli 
AUC    Area Under the Curve 
BCA    Bicinchoninic Acid Assay 
BRAF    v-Raf Murine Sarcoma Viral Oncogene Homolog B 
BSA    Bovine Serum Albumin 
CA 19-9   Carbohydrate Antigen 19-9, tumor marker 
CA11-19   Colorectal Cancer Tumor marker 
CAA    Colorectal Advanced Adenoma 
CCD 841   Human Normal Colon Epithelial Cell Line 
CEA    Carcinoembryonic Antigen, tumor marker
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CIMP    CpG Island Methylator Phenotype 
CIN    Chromosomal Instability 
CRC    Colorectal Cancer 
DMEM   Dulbecco’s Modified Eagle’s Medium 
DMSO    Dimethyl Sulfoxide 
DNA    Deoxyribonucleic Acid 
dTMP    Deoxythymidine Monophosphate 
dUMP    Deoxyuridine Monophosphate 
EDTA    Ethylenediaminetetraacetic Acid 
EGFR    Epidermal Growth Factor Receptor 
ELISA    Enzyme-Linked Immunosorbent Assay 
EMEM   Eagle’s Minimum Essential Medium 
EMT    Epithelial-Mesenchymal Transition 
ERK 1/2  Extracellular Signal-Related Kinase pathway; part of the 
MAPK 
EtOH    Ethanol 
FAP    Familial Adenomatous Polyposis 
FBS    Fetal Bovine Serum 
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FOBT    Fecal Occult Blood Test 
FOG2    Friend of GATA 2 
FOLFOX Chemotherapy Regimen, FOL – Folinic Acid (Leucovorin), 
F – Fluorouracil (5-FU), OX - Oxaliplatin 
GDP    Guanosine Diphosphate 
Grb2-SOS1 Growth Factor Receptor-Bound Protein 2 – Son of 
Sevenless homolog 1 
GTP    Guanosine Triphosphate 
HNPCC   Hereditary Nonpolyposis Colorectal Cancer 
HRAS    Harvey Rat Sarcoma Viral Oncogene Homolog 
IPA    Ingenuity Pathway Analysis 
JNK c-Jun N-terminal Kinase pathway; part of the MAPK 
pathway 
KRAS    Kirsten Rat Sarcoma Viral Oncogene Homolog 
HT-29    Human Dukes’ C Colorectal Adenocarcinoma Cell Line 
M-    miRNA Mimic Negative Control 
MAPK    Mitogen-Activated Protein Kinase 
MAPKK / MAP2K  Mitogen-Activated Protein Kinase Kinase 
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MAPKKK / MAP3K  Mitogen-Activated Protein Kinase Kinase Kinase 
MAPK14   Mitogen-Activated Protein Kinase 14, also called p38-α 
MEK 1/2  Mitogen-Activated Protein Kinase Kinase; phosphorylates 
mitogen-Activated protein kinase 
MET    Mesenchymal-Epithelial Transition 
miRNA   microRNA: short, single stranded RNA 
MLH1    MutL Homolog 1 
MMR    Mismatch Repair 
MOSAIC Multicenter International Study of Oxaliplatin/5-
Fluororuracil/Leucovorin in the Adjuvant Treatment of 
Colon Cancer Trial 
mRNA messengerRNA: longer, single stranded RNA; serves as a 
template for protein translation 
MSI    Microsatellite Instability 
MSS    Microsatellite Stable 
NRAS    Neuroblastoma Rat Sarcoma Viral Oncogene Homolog 
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit alpha 
PKC    Protein Kinase C 
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qRT-PCR Real-Time Quantitative Reverse Transcription Polymerase 
Chain Reaction 
RASSF2   Ras Association Domain-Containing Protein 2 
RIPA    Radioimmunoprecipitation Assay Buffer 
RISC    RNA-Induced Silencing Complex 
RNA    Ribonucleic Acid 
S6K    Ribosomal Protein (S6) Kinase 
SNAIL   Zinc Finger Protein SNAI1 
siRNA Short Interfering RNA; synthetic RNA duplex designed to 
specifically target a particular mRNA for degradation 
SW1116   Human Dukes’ A Colorectal Adenocarcinoma Cell Line 
SW480   Human Dukes’ B Colorectal Adenocarcinoma Cell Line 
T84    Human Dukes’ D Colorectal Adenocarcinoma Cell Line  
TBS-T    Tris-Buffered Saline and Polysorbate 20 
TGF-β    Transforming Growth Factor Beta 
TNM Tumor, Node, Metastasis Classification of Malignant 
Tumors 
TP53    Tumor Protein p53 
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TS    Thymidylate Synthase 
Wnt Wingless-Related Integration Site; Signal transduction 
pathway 
ZEB 1/2    Zinc Finger E-box Binding Homeobox 1/2  
5-FU    5-Fluorouracil  
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As part of my interest in teaching I have initially been involved with research into medical 
education, both at an undergraduate and postgraduate level. As part of my year as a clinical 
teaching fellow I was involved in several research projects, 4 of them as principle researcher. 
Completion of these projects has led to presentations at an international conference. Following 
this, I have been involved as joint lead in a postgraduate surgical education research project. My 
interest and experience in research has led me to be involved with a large multicentre national 
audit as a collaborator.  
The principles behind research fascinate me, and as a result I wish to pursue a career in academic 
general surgery. My rotations to date have led me to have an interest in colorectal disease, in 
particular colorectal cancer.  With my long term interest in general surgery I have also been 
awarded the Price Institute Surgical Research Fellowship, University of Louisville, Kentucky 
USA. I commenced this post in October 2014 where I am studying towards a PhD on the role of 
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POSITIONS OF RESPONSIBILITY / MANAGEMENT 
 
I enjoy taking on managerial responsibilities and projects requiring organisation and leadership 
qualities. I am effective at motivating people and achieving set goals. I have taken on roles, both 
in my clinical work and outside of medicine, which show my enthusiasm to develop these skills. I 
realise that management is an integral part of hospital practice and have so far had the following 
experience in management. 
 
The Society for 




The SSAT is committed to advancing the science 
and practice of surgery in the treatment of digestive 
disease. 
2016 
Ad hoc journal 
reviewer for Diseases of 
the Colon and Rectum   
Reviewer of manuscripts submitted to the world’s 
leading peer-reviewed journal in colorectal surgery 
(impact factor 3.739). My specialist interest being 








Junior representative on restructuring of the 
emergency surgery service in North Bristol NHS 
Trust following relocation to Southmead Hospital - 






Junior lead for commissioning of breast/plastics 
theatres in North Bristol NHS Trust. Liaison 
amongst multidisciplinary team members and voice 








Junior Doctor representative and attendance at 










Organisation of the breast surgery rota for junior 




Medical School Course 
Planning 
During my year as a Clinical Teaching Fellow I 
was instrumental in curriculum planning and 









Organiser for 20 6th form students from local 
comprehensive schools interested in applying for 
medicine to attend a week long summer school. 






Lead organiser for recruitment and provision of 
simulation training using SIMman for both 
undergraduate medical and nursing students. 





MBChB Surgical Skills 
programme 
 
Lead organiser of final year MBChB Surgical 






Organiser and faculty member of Core Surgical 




Trauma Simulation Organiser of multi-disciplinary trauma simulation 







Medical Officer at Point-to-Point Horse Trials. 
Responsible for jockey and crowd safety. Gelligaer 











Ski club captain 
 
University of Bristol Medics ski club captain and 
organiser of ski trip for 50 students 
 
2006-2007 
Captain of Sports 
Teams 
 
Captained lacrosse, netball and hockey 1st teams at 














I have taken an interest in teaching throughout my postgraduate career. My experience so far, as 
well as informal student teaching includes: 
QUALIFICATIONS 
Postgraduate Certificate in Medical Education     2013 
Teaching and learning for Health Professionals. University of Bristol 
Fellow of the Higher Education Academy      2013 
Training the Trainers         2011 
Royal College of Surgeons of England  
Formal (Full-Time) Teaching Roles 
Clinical Teaching 
Fellow 
University of Bristol, 
Gloucestershire Royal 
Hospital 
Delivery of medicine and surgery curriculum to 3rd 
and 5th year medical students from the University 
of Bristol. Involvement with evaluation and 
restructuring of the undergraduate surgical 
education. Provision of clinical teaching, small 
group teaching, lecturing, feedback sessions, 
pastoral support and examination setting and 
marking. In addition to medicine and surgery, I 
was also responsible for delivery of professional 
behaviour standards, ethics and communication 
and equality and diversity teaching. I was also 
involved with course development and design for 
core surgical skills. 
During this post, I managed to maximize the 
opportunities for my own clinical learning within 






Other Teaching Roles 
University of Louisville, 
School of Medicine 
 
Core Surgical Trainees 
Teaching, Severn and 
Peninsula Deaneries 
Oral examiner of Year 3 Medical Students Surgical 
Rotation 
 
Faculty for core surgical skills days. Organisation 






Introduction to Medical 
Education, Course Faculty 
 
Invited as speaker and faculty to deliver course on 
introduction to medical education to surgical 
trainees. 
2012-2014 
Honorary Clinical Surgical 
Tutor 
Severn School of Surgery 
Awarded for delivering teaching to core surgical 
trainees 
2011-2013 
Examiner for Final 
MBChB OSLER & OSCE 
University of Bristol 
Regular examiner of long case and OSCE exams 
for final year medical students 
2011-2013 
Examiner, Marker & 
Invigilator  
MBChB OSCE & Data 
OSCE 
University of Bristol 
Regular examiner, marker and invigilator for 3rd 




University of Bristol 
 
Invited to interview 6th form and postgraduate 




Intermediate Life Support 
Course Faculty 
 
Course facilitator for final year medical students 2012 




Invited to conduct interview practice for 
foundation year 2 trainees applying for specialty 
training 
2012 
Honorary Clinical Tutor 
University of Bristol 
 
Awarded for delivering teaching to University of 
Bristol Medical Students 
2011-2012 
Student Selected 
Component (SSC) Marker 
University of Bristol 
 
Marker of Year 4 MBChB students SSC’s. 
Required to mark 20 3,000 word reports to count 
towards overall grade 
2011 
Student Mentor 
Musgrove Park Hospital 
University of Bristol 





OUTSIDE INTERESTS AND ACHIEVEMENTS 
 
 
Tennis:  USTA League 18 & Over, Louisville, KY  2015- 
  Women’s State Champions (Lexington, KY)  2016 
  Mixed Doubles State Champions (Murray, KY)  2016 
  Women’s Doubles Combo State Champions (Lexington, KY)  2016 
Badminton:  Durham County Elite Squad  98-02 
Lacrosse:  Polam Hall School for Girls 1st XII Captain  00-02 
Netball:  Polam Hall School for Girls 1st VII Captain  00-02 
  Player of the Year  01-02 
Hockey:  University of Bristol 2nd X1  02-04 
  Polam Hall School for Girls 1st XI Vice-Captain  00-02 
Football:  University of Bristol Medical School 1st XI Vice-Captain  04-07  
  Player of the Year  06-07 
 
Sport has always played a major part in my life. I currently take time to maintain my health by 
playing tennis. I have recently represented Kentucky at the Southern Sectional tennis 
championships in Mobile, AL, playing against the champions of eight other southern states for 
the opportunity to advance to the National finals.  
I am a keen traveler and as such I have visited many countries ranging from developed to under-
developed and have experienced many different cultures and religions. 
 
 
